foscarnet has been researched along with Herpes Simplex Virus Infection in 138 studies
Foscarnet: An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpesviruses and HIV.
phosphonoformic acid : Phosphoric acid in which one of the hydroxy groups is replaced by a carboxylic acid group. It is used as the trisodium salt as an antiviral agent in the treatment of cytomegalovirus retinitis (CMV retinitis, an inflamation of the retina that can lead to blindness) and as an alternative to ganciclovir for AIDS patients who require concurrent antiretroviral therapy but are unable to tolerate ganciclovir due to haematological toxicity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The efficacy and toxicity of foscarnet cream for the treatment of mucocutaneous herpes simplex virus lesions or lesions that were clinically unresponsive to systemic acyclovir treatment (median, 30." | 9.09 | Treatment of mucocutaneous herpes simplex virus infections unresponsive to acyclovir with topical foscarnet cream in AIDS patients: a phase I/II study. ( Bryson, Y; Grafford, K; Hardy, WD; Javaly, K; Kalayjian, R; Klein, T; Martin-Munley, S; Wohlfeiler, M, 1999) |
| "The safety and efficacy of cidofovir gel for treatment of acyclovir-unresponsive herpes simplex virus infections in AIDS patients was evaluated in a randomized, double-blind, multicenter trial." | 9.08 | A randomized, double-blind, placebo-controlled trial of cidofovir gel for the treatment of acyclovir-unresponsive mucocutaneous herpes simplex virus infection in patients with AIDS. ( Boggs, J; Cheung, T; Corey, L; Drew, WL; Feinberg, J; Gathe, J; Jaffe, HS; Kessler, H; Kramer, F; Lalezari, J; Lee, S; McGuire, B; Safrin, S; Schacker, T, 1997) |
| "Herpes simplex virus (HSV) resistant to acyclovir can produce persistent mucocutaneous ulcerative disease in patients with the acquired immunodeficiency syndrome (AIDS)." | 9.07 | Foscarnet treatment of acyclovir-resistant herpes simplex virus infection in patients with acquired immunodeficiency syndrome: preliminary results of a controlled, randomized, regimen-comparative trial. ( Hardy, WD, 1992) |
| "Persons with AIDS who have CD4+ counts < or = 100 and transplant patients, especially bone marrow allograft recipients, may experience clinically significant infections with acyclovir-resistant herpes simplex virus (HSV) or varicella-zoster virus (VZV)." | 8.79 | Management of acyclovir-resistant herpes simplex and varicella-zoster virus infections. ( Balfour, HH; Benson, C; Braun, J; Cassens, B; Erice, A; Friedman-Kien, A; Klein, T; Polsky, B; Safrin, S, 1994) |
| "Acyclovir can prevent the establishment of latent herpes simplex virus (HSV) in sensory ganglia by early treatment of the primary infection in experimental animals." | 8.76 | Treatment of experimental latent herpes simplex virus infections with acyclovir and other antiviral compounds. ( Klein, RJ, 1982) |
| " While the routine use of prophylactic acyclovir has reduced the incidence of herpes simplex virus (HSV) reactivation, there is an increasing prevalence of acyclovir resistance within this cohort of patients." | 8.02 | Unusual oral presentation of acyclovir-resistant herpes simplex in an allogeneic haematopoietic stem cell transplant recipient. ( Harte, M; Ion, D; Saunsbury, T, 2021) |
| "We report on patients who developed severe acyclovir-resistant (ACVr) herpes simplex virus 1 (HSV-1) stomatitis after allogeneic hematopoietic cell transplantation (HCT)." | 7.96 | Topical Treatment of Acyclovir-Resistant Herpes Simplex Virus Stomatitis after Allogeneic Hematopoietic Cell Transplantation. ( Heidenreich, D; Hofmann, WK; Jawhar, M; Klein, SA; Kreil, S; Mueller, N; Nolte, F, 2020) |
| "To report use of intravenous foscarnet or cidofovir for the treatment of refractory acute retinal necrosis (ARN)." | 7.88 | Treatment of Refractory Acute Retinal Necrosis with Intravenous Foscarnet or Cidofovir. ( Barshak, MB; Durand, ML; Foster, CS; Kim, IK; Mali, JO; Scott, NL; Stryjewski, TP; Tobin, EH; Young, LH, 2018) |
| "Acyclovir resistance is rarely seen in herpes simplex virus (HSV) type I encephalitis." | 7.85 | Acyclovir resistance in herpes simplex virus type I encephalitis: a case report. ( Beer, R; Bergmann, M; Helbok, R; Kofler, M; Pfausler, B; Schmutzhard, E, 2017) |
| " Herpes simplex virus (HSV) reactivations are usually prevented by acyclovir (ACV) prophylaxis, whereas cidofovir (CDV) has been used off indication to manage AdV infections." | 7.83 | Brincidofovir clearance of acyclovir-resistant herpes simplex virus-1 and adenovirus infection after stem cell transplantation. ( Edelmann, A; Hofmann, J; Kühl, JS; Sauerbrei, A; Voigt, S, 2016) |
| "Acyclovir-resistant herpes simplex virus (HSV) infection is common in immunocompromised patients, but the course of such infection is little known." | 7.80 | Long-term follow-up of HIV-infected patients once diagnosed with acyclovir-resistant herpes simplex virus infection. ( Agut, H; Boutolleau, D; Burrel, S; Caumes, E; Epelboin, L; Katlama, C; Regnier, S; Seang, S; Valantin, MA; Voujon, D, 2014) |
| "To study the effects of intravitreal foscarnet and the clinical differences between varicella zoster virus (VZV) and herpes simplex virus (HSV) induced acute retinal necrosis (ARN)." | 7.76 | Acute retinal necrosis: the effects of intravitreal foscarnet and virus type on outcome. ( Graham, EM; Laidlaw, DA; Pavesio, CE; Stanford, MR; Williamson, TH; Wong, R, 2010) |
| "Diagnosis and management of Acute Retinal Necrosis (ARN) in children that does not respond to systemic acyclovir treatment can be challenging." | 7.73 | Intravenous foscarnet in the management of acyclovir-resistant herpes simplex virus type 2 in acute retinal necrosis in children. ( Charonis, A; Gupta, A; Khurana, RN; Samuel, MA; Tawansy, KA, 2005) |
| " The patient had a history of acyclovir (ACV)-resistant (ACV(r)) herpes simplex virus type 1 (HSV-1) infections prior to BMT." | 7.71 | Bone marrow transplantation in a child with Wiskott-Aldrich syndrome latently infected with acyclovir-resistant (ACV(r)) herpes simplex virus type 1: emergence of foscarnet-resistant virus originating from the ACV(r) virus. ( De Clercq, E; Kato, S; Kurane, I; Maeda, A; Morikawa, S; Niikura, M; Saijo, M; Suzutani, T; Yabe, H; Yasuda, Y, 2002) |
| "The influence of sodium lauryl sulfate (SLS) on the efficacies of gel formulations of foscarnet against herpes simplex virus type 1 (HSV-1) cutaneous lesions and on the establishment and reactivation of latent virus has been evaluated in a murine model of orofacial infection." | 7.71 | Efficacies of gel formulations containing foscarnet, alone or combined with sodium lauryl sulfate, against establishment and reactivation of latent herpes simplex virus type 1. ( Bergeron, MG; Désormeaux, A; Lamontagne, J; Piret, J, 2001) |
| "Over an eight-month period from October 1997 to May 1998, four patients who had received bone marrow transplant (BMT) from unrelated donor presented with severe mucosal cutaneous infections involving acyclovir resistant herpes simplex virus 1 (HSV-1)." | 7.71 | Infection due to acyclovir resistant herpes simplex virus in patients undergoing allogeneic hematopoietic stem cell transplantation. ( Bordigoni, P; Carret, AS; Corsaro, D; Dauendorffer, JN; Edert, D; Le Faou, A; Venard, V, 2001) |
| "A leukemic child developed recurrent herpes simplex virus lesions shortly after receiving a bone marrow transplant and while taking acyclovir." | 7.71 | Successful treatment of foscarnet-resistant herpes simplex stomatitis with intravenous cidofovir in a child. ( Bryant, P; Carapetis, J; Curtis, N; Sasadeusz, J; Waters, K, 2001) |
| "Genotypic analysis of herpes simplex virus (HSV) DNA extracted from clinical specimens from a case of fatal disseminated neonatal HSV demonstrated that an infant developed an acyclovir-resistant HSV containing a mutation in the HSV thymidine kinase gene during the first seven days of acyclovir therapy." | 7.71 | Development of acyclovir-resistant herpes simplex virus early during the treatment of herpes neonatorum. ( Leary, JJ; Levin, MJ; Sarisky, RT; Weinberg, A, 2001) |
| "The objective of this study was to investigate the prevalence of resistance of herpes simplex virus to acyclovir and foscarnet." | 7.71 | [In vitro susceptibility study of herpes simplex virus to acyclovir and foscarnet. Are routine susceptibility studies necessary?]. ( Cañizares, A; Guerrero, A; Hellín, T; Losada, I; Martí-Belda, P, 2002) |
| "Sequential herpes simplex virus (HSV) isolates from AIDS patients receiving foscarnet therapy were evaluated for susceptibility to adefovir." | 7.71 | Herpes simplex virus isolates with reduced adefovir susceptibility selected in vivo by foscarnet therapy. ( Bestman-Smith, J; Boivin, G, 2002) |
| "Herpes simplex virus (HSV) isolates were characterized from 8 AIDS patients in whom acyclovir and foscarnet therapy sequentially failed." | 7.70 | Characterization of the DNA polymerase and thymidine kinase genesof herpes simplex virus isolates from AIDS patients in whom acyclovirand foscarnet therapy sequentially failed. ( Boivin, G; Schmit, I, 1999) |
| "The efficacy of intravitreal foscarnet injections was evaluated in a rabbit model of Herpes simplex virus type-1 (HSV-1) retinitis." | 7.70 | Reducing chorioretinal viral counts with intravitreal foscarnet injections in a rabbit model of Herpes simplex virus type-1 retinitis. ( Beauchamp, D; Bergeron, MG; Delorme, C; Désormeaux, A; Gourde, P; Morin, NJ; Omar, RF; Rousseau, A; Tremblay, MJ, 1999) |
| "The topical efficacies of foscarnet and acyclovir incorporated into a polyoxypropylene-polyoxyethylene polymer were evaluated and compared to that of 5% acyclovir ointment (Zovirax) by use of a murine model of cutaneous herpes simplex virus type 1 infection." | 7.70 | Efficacies of topical formulations of foscarnet and acyclovir and of 5-percent acyclovir ointment (Zovirax) in a murine model of cutaneous herpes simplex virus type 1 infection. ( Bergeron, MG; Désormeaux, A; Gourde, P; Juhász, J; Piret, J, 2000) |
| "The influence of sodium lauryl sulfate (SLS) on the efficacies of topical gel formulations of foscarnet against herpes simplex virus type 1 (HSV-1) cutaneous infection has been evaluated in mice." | 7.70 | Sodium lauryl sulfate increases the efficacy of a topical formulation of foscarnet against herpes simplex virus type 1 cutaneous lesions in mice. ( Bergeron, MG; Cormier, H; Désormeaux, A; Gourde, P; Juhász, J; Lamontagne, J; Piret, J, 2000) |
| " One patient with AIDS suffered from a perineal lesion due to infection with herpes simplex virus type 2 (HSV-2) and did not respond to acyclovir and was intolerant of foscarnet." | 7.69 | Successful treatment of progressive mucocutaneous infection due to acyclovir- and foscarnet-resistant herpes simplex virus with (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC). ( Andrei, G; Balzarini, J; Clumeck, N; De Clercq, E; Gérard, M; Hedderman, A; Sadzot-Delvaux, C; Silverman, A; Snoeck, R; Tricot, G, 1994) |
| "We established a quantitative flow cytometric method for determination of herpes simplex virus type 1 (HSV-1) susceptibility to acyclovir (ACV), ganciclovir, and foscarnet in vitro." | 7.69 | Flow cytometric analysis of herpes simplex virus type 1 susceptibility to acyclovir, ganciclovir, and foscarnet. ( Hampl, W; Hartmann, A; Mertens, T; Michel, D; Pavić, I; Schleyer, I; Zimmermann, A, 1997) |
| "A 41-year-old recipient of matched unrelated BMT acquired a severe mucocutaneous herpes simplex virus (HSV) type I infection during acyclovir prophylaxis." | 7.68 | Successful foscarnet therapy for acyclovir-resistant mucocutaneous infection with herpes simplex virus in a recipient of allogeneic BMT. ( Cornelissen, JJ; de Gast, GC; Dekker, AW; Lepoutre, J; Rozenberg-Arska, M; Smit, J; Verdonck, LF, 1993) |
| "Resistance of herpes simplex virus to acyclovir is a problem of growing clinical importance." | 7.68 | Heterogeneity of a herpes simplex virus clinical isolate exhibiting resistance to acyclovir and foscarnet. ( Coen, DM; Hicks, KA; Pelosi, E; Sacks, SL, 1992) |
| "Foscarnet (trisodium phosphonoformate), an investigational pyrophosphate analog increasingly used to treat refractory cytomegalovirus retinitis and mucocutaneous herpes simplex virus infections in immunocompromised patients, has been reported to cause abnormalities in serum calcium and phosphate, including cases of fatal hypocalcemia." | 7.68 | Foscarnet-induced hypocalcemia and effects of foscarnet on calcium metabolism. ( Aweeka, FT; Causey, DM; Gambertoglio, JG; Jacobson, MA; Portale, AA, 1991) |
| "Mucocutaneous herpes simplex virus (HSV) infections that are resistant to therapy with acyclovir have been recognized with increasing frequency in patients with the acquired immunodeficiency syndrome, although alternative therapies in this setting have not been widely studied." | 7.68 | Foscarnet therapy for acyclovir-resistant mucocutaneous herpes simplex virus infection in 26 AIDS patients: preliminary data. ( Assaykeen, T; Follansbee, S; Mills, J; Safrin, S, 1990) |
| "Three marrow transplant patients developed pneumonia due to acyclovir-resistant thymidine-kinase-deficient herpes simplex virus (HSV) type 1." | 7.68 | Acyclovir-resistant herpes simplex virus causing pneumonia after marrow transplantation. ( Ellis, MN; Hackman, RC; Ljungman, P; Meyers, JD; Shepp, DH, 1990) |
| "To determine whether trisodium phosphonoformate (foscarnet) is efficacious in treating severe mucocutaneous disease due to acyclovir-resistant herpes simplex virus type-2 (HSV-2) infection in patients with the acquired immunodeficiency syndrome (AIDS)." | 7.67 | Foscarnet therapy for severe acyclovir-resistant herpes simplex virus type-2 infections in patients with the acquired immunodeficiency syndrome (AIDS). An uncontrolled trial. ( Drennan, DP; Erlich, KS; Follansbee, SE; Gooze, L; Jacobson, MA; Koehler, JE; Mills, J; Safrin, S, 1989) |
| "The influence of (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU), caffeic acid oxidation product (KOP), and trisodiumphosphonoformate (TPF) on the course of the primary cutaneous herpes simplex virus infection was investigated by means of a guinea pig test model." | 7.67 | Therapeutic effect of (E)-5-(2-bromovinyl)-2'-deoxyuridine, caffeic acid oxidation product, and trisodiumphosphonoformate on cutaneous herpes simplex virus type 1 infection in guinea pigs. ( Helbig, B; Herrmann, G; Klöcking, R; Sauerbrei, A; Wicht, N; Wiedemann, U; Wutzler, P, 1987) |
| "The sensitivity of different herpes simplex virus type 2 (HSV-2) strains to inhibition by 5-vinyl-1-beta-D-arabinofuranosyluracil (VaraU) was evaluated in comparison to 9-(2-hydroxyethoxymethyl)guanine (ACV; acyclovir) and trisodiumphosphonoformate (Na3PFA; foscarnet), using a plaque inhibition assay in primary rabbit testes (PRT) cells as well as in human embryonic lung fibroblast (HELF) cell cultures." | 7.67 | Efficacy of 5-vinyl-1-beta-D-arabinofuranosyluracil (VaraU) against herpes simplex virus type 2 strains in cell cultures and against experimental herpes encephalitis in mice: comparison with acyclovir and foscarnet. ( Herrmann, G; Reefschläger, J; Thiel, KD; Wutzler, P, 1987) |
| "Topical foscarnet (PFA) and acyclovir (ACV) were compared in the dorsal cutaneous guinea pig model of herpes simplex virus type 1 infection." | 7.67 | Comparison of foscarnet cream, acyclovir cream, and acyclovir ointment in the topical treatment of experimental cutaneous herpes simplex virus type 1 infection. ( Freeman, DJ; Sheth, NV; Spruance, SL, 1986) |
| "Methoxymethyldeoxyuridine (MMUdR) when used in combination with either trifluorothymidine (F3TdR) or phosphonoformate (PFA) showed synergistic activity against herpes simplex virus type 1 and type 2 (HSV-1 and HSV-2) in vitro, whereas MMUdR and acycloguanosine (ACG) combination was antagonistic against herpes viruses." | 7.67 | Combination chemotherapy: interaction of 5-methoxymethyldeoxyuridine with trifluorothymidine, phosphonoformate and acycloguanosine against herpes simplex viruses. ( Ayisi, NK; Babiuk, LA; Gupta, SV, 1985) |
| "The efficiency of (E)-5-(2-bromovinyl)- and 5-vinyl-1-beta-D-arabinofuranosyluracil (BrVaraU, VaraU) as inhibitors of three herpes simplex virus type 1 (HSV-1) strains was assessed in comparison to (E)-5-(2-bromovinyl)-2'-deoxyuridine (BrVUdR), 9-(2-hydroxyethoxymethyl)guanine (ACV), and trisodium phosphonoformate (Na3PFA) using a plaque assay in human embryonic lung fibroblast (HELF) cell cultures." | 7.67 | Treatment of experimental herpes simplex virus type 1 encephalitis in mice with (E)-5-(2-bromovinyl)- and 5-vinyl-1-beta-D-arabinofuranosyluracil: comparison with bromovinyl-deoxyuridine and acyclovir. ( Herrmann, G; Reefschläger, J; Thiel, KD; Wutzler, P, 1986) |
| "The therapeutic effects of topically applied foscarnet sodium and acyclovir on cutaneous infections due to herpes simplex virus type 1 (HSV-1) were studied in guinea pigs." | 7.66 | Therapeutic effects of foscarnet sodium and acyclovir on cutaneous infections due to herpes simplex virus type 1 in guinea pigs. ( Alenius, S; Berg, M; Broberg, F; Eklind, K; Lindborg, B; Oberg, B, 1982) |
| " The dosage of foscarnet should be 40 milligrams per kilogram three times per day or 60 milligrams per kilogram twice daily." | 6.42 | Management of acyclovir-resistant herpes simplex virus. ( Chilukuri, S; Rosen, T, 2003) |
| "Genital herpes is an important cofactor for acquisition of human immunodeficiency virus (HIV) infection, and effective prophylaxis is a helpful strategy to halt both HIV and herpes simplex virus (HSV) transmission." | 5.48 | The Anti-Human Immunodeficiency Virus Drug Tenofovir, a Reverse Transcriptase Inhibitor, Also Targets the Herpes Simplex Virus DNA Polymerase. ( Andrei, G; Gillemot, S; Snoeck, R; Topalis, D, 2018) |
| "Imiquimod treatment also appeared to delay the time to recurrence of HSV lesions." | 5.38 | Successful treatment of aciclovir and foscarnet resistant Herpes simplex virus lesions with topical imiquimod in patients infected with human immunodeficiency virus type 1. ( Agut, H; Caumes, E; Challine, D; Deback, C; Lascaux, AS; Lévy, Y; Melica, G, 2012) |
| "Foscarnet is a non-thymidine kinase-dependent agent, but the emergence of ACV and foscarnet-resistant HSV requires a new therapeutic approach." | 5.31 | Treatment of an acyclovir and foscarnet-resistant herpes simplex virus infection with cidofovir in a child after an unrelated bone marrow transplant. ( Blot, N; Dehesdin, D; Janvresse, C; Schneider, P; Tron, P; Vannier, JP; Young, P, 2000) |
| "Virus isolates from four AIDS patients and one bone marrow transplant recipient were examined for their sensitivity for the antiviral compounds used by means of plaque reduction assay." | 5.28 | [Acyclovir-resistant herpes simplex virus infections in immunocompromised patients]. ( Frissen, PH; Jansen, CL; Maris-Tegeler, WG; van der Noordaa, J; Weiland, HT; Wertheim-van Dillen, PM, 1992) |
| "The efficacy and toxicity of foscarnet cream for the treatment of mucocutaneous herpes simplex virus lesions or lesions that were clinically unresponsive to systemic acyclovir treatment (median, 30." | 5.09 | Treatment of mucocutaneous herpes simplex virus infections unresponsive to acyclovir with topical foscarnet cream in AIDS patients: a phase I/II study. ( Bryson, Y; Grafford, K; Hardy, WD; Javaly, K; Kalayjian, R; Klein, T; Martin-Munley, S; Wohlfeiler, M, 1999) |
| "The safety and efficacy of cidofovir gel for treatment of acyclovir-unresponsive herpes simplex virus infections in AIDS patients was evaluated in a randomized, double-blind, multicenter trial." | 5.08 | A randomized, double-blind, placebo-controlled trial of cidofovir gel for the treatment of acyclovir-unresponsive mucocutaneous herpes simplex virus infection in patients with AIDS. ( Boggs, J; Cheung, T; Corey, L; Drew, WL; Feinberg, J; Gathe, J; Jaffe, HS; Kessler, H; Kramer, F; Lalezari, J; Lee, S; McGuire, B; Safrin, S; Schacker, T, 1997) |
| "Herpes simplex virus (HSV) resistant to acyclovir can produce persistent mucocutaneous ulcerative disease in patients with the acquired immunodeficiency syndrome (AIDS)." | 5.07 | Foscarnet treatment of acyclovir-resistant herpes simplex virus infection in patients with acquired immunodeficiency syndrome: preliminary results of a controlled, randomized, regimen-comparative trial. ( Hardy, WD, 1992) |
| "Herpes simplex virus (HSV) infections are efficiently treated with antiviral drugs such as acyclovir (ACV)." | 4.82 | Herpes simplex virus resistance to antiviral drugs. ( Morfin, F; Thouvenot, D, 2003) |
| "Persons with AIDS who have CD4+ counts < or = 100 and transplant patients, especially bone marrow allograft recipients, may experience clinically significant infections with acyclovir-resistant herpes simplex virus (HSV) or varicella-zoster virus (VZV)." | 4.79 | Management of acyclovir-resistant herpes simplex and varicella-zoster virus infections. ( Balfour, HH; Benson, C; Braun, J; Cassens, B; Erice, A; Friedman-Kien, A; Klein, T; Polsky, B; Safrin, S, 1994) |
| "The nucleoside analog acyclovir is remarkably effective and selective in herpes simplex virus (HSF) infections." | 4.78 | [Resistance of herpes simplex viruses to antiviral drugs]. ( Bianchi, A; Scieux, C, 1993) |
| "Acyclovir can prevent the establishment of latent herpes simplex virus (HSV) in sensory ganglia by early treatment of the primary infection in experimental animals." | 4.76 | Treatment of experimental latent herpes simplex virus infections with acyclovir and other antiviral compounds. ( Klein, RJ, 1982) |
| "Data on herpes simplex virus (HSV) polymorphism as well as acyclovir (ACV) and foscarnet (FOS) resistance mutations are not exhaustive and may hinder accurate diagnosis by next-generation sequencing (NGS)." | 4.31 | Novel UL23 and UL30 substitutions in HSV1 and HSV2 viruses related to polymorphism or drug resistance. ( Ader, F; Billaud, G; Boyer, T; Destras, G; Ducastelle, S; Frobert, E; Ginevra, C; Giorgi, J; Josset, L; Morfin, F; Regue, H; Semanas, Q; Simon, B, 2023) |
| " While the routine use of prophylactic acyclovir has reduced the incidence of herpes simplex virus (HSV) reactivation, there is an increasing prevalence of acyclovir resistance within this cohort of patients." | 4.02 | Unusual oral presentation of acyclovir-resistant herpes simplex in an allogeneic haematopoietic stem cell transplant recipient. ( Harte, M; Ion, D; Saunsbury, T, 2021) |
| "Acyclovir (ACV) and penciclovir and their prodrugs are recommended for therapy or prophylaxis of Herpes simplex virus 1 (HSV-1) infections." | 4.02 | Antiviral susceptibility of recombinant Herpes simplex virus 1 strains with specific polymerase amino acid changes. ( Baukmann, S; Brunnemann, AK; Bühler, S; Fickenscher, H; Krumbholz, A; Rose, R; Sauerbrei, A; Zell, R, 2021) |
| "We report on patients who developed severe acyclovir-resistant (ACVr) herpes simplex virus 1 (HSV-1) stomatitis after allogeneic hematopoietic cell transplantation (HCT)." | 3.96 | Topical Treatment of Acyclovir-Resistant Herpes Simplex Virus Stomatitis after Allogeneic Hematopoietic Cell Transplantation. ( Heidenreich, D; Hofmann, WK; Jawhar, M; Klein, SA; Kreil, S; Mueller, N; Nolte, F, 2020) |
| "To report use of intravenous foscarnet or cidofovir for the treatment of refractory acute retinal necrosis (ARN)." | 3.88 | Treatment of Refractory Acute Retinal Necrosis with Intravenous Foscarnet or Cidofovir. ( Barshak, MB; Durand, ML; Foster, CS; Kim, IK; Mali, JO; Scott, NL; Stryjewski, TP; Tobin, EH; Young, LH, 2018) |
| "Acyclovir resistance is rarely seen in herpes simplex virus (HSV) type I encephalitis." | 3.85 | Acyclovir resistance in herpes simplex virus type I encephalitis: a case report. ( Beer, R; Bergmann, M; Helbok, R; Kofler, M; Pfausler, B; Schmutzhard, E, 2017) |
| " Herpes simplex virus (HSV) reactivations are usually prevented by acyclovir (ACV) prophylaxis, whereas cidofovir (CDV) has been used off indication to manage AdV infections." | 3.83 | Brincidofovir clearance of acyclovir-resistant herpes simplex virus-1 and adenovirus infection after stem cell transplantation. ( Edelmann, A; Hofmann, J; Kühl, JS; Sauerbrei, A; Voigt, S, 2016) |
| "Acyclovir-resistant herpes simplex virus (HSV) infection is common in immunocompromised patients, but the course of such infection is little known." | 3.80 | Long-term follow-up of HIV-infected patients once diagnosed with acyclovir-resistant herpes simplex virus infection. ( Agut, H; Boutolleau, D; Burrel, S; Caumes, E; Epelboin, L; Katlama, C; Regnier, S; Seang, S; Valantin, MA; Voujon, D, 2014) |
| " Here, we present a case of a successful clearance of a perianal acyclovir resistant and foscarnet refractory herpes simplex virus (HSV1) ulcer in a 34 year-old woman who had undergone allogeneic hematopoietic stem cell transplantation." | 3.79 | Successful clearance of cutaneous acyclovir-resistant, foscarnet-refractory herpes virus lesions with topical cidofovir in an allogeneic hematopoietic stem cell transplant patient. ( Armistead, P; Dean, A; Khan, T; Muluneh, B, 2013) |
| "To study the effects of intravitreal foscarnet and the clinical differences between varicella zoster virus (VZV) and herpes simplex virus (HSV) induced acute retinal necrosis (ARN)." | 3.76 | Acute retinal necrosis: the effects of intravitreal foscarnet and virus type on outcome. ( Graham, EM; Laidlaw, DA; Pavesio, CE; Stanford, MR; Williamson, TH; Wong, R, 2010) |
| "Diagnosis and management of Acute Retinal Necrosis (ARN) in children that does not respond to systemic acyclovir treatment can be challenging." | 3.73 | Intravenous foscarnet in the management of acyclovir-resistant herpes simplex virus type 2 in acute retinal necrosis in children. ( Charonis, A; Gupta, A; Khurana, RN; Samuel, MA; Tawansy, KA, 2005) |
| "Immunocompromised patients are developing in an increasing frequency acyclovir-resistant herpes simplex infections." | 3.72 | [Acyclovir-resistant herpes exulcerans et persistens. Type II]. ( Klammer, M; Kuhn, A; Ruzicka, T; Stege, H, 2003) |
| " The patient had a history of acyclovir (ACV)-resistant (ACV(r)) herpes simplex virus type 1 (HSV-1) infections prior to BMT." | 3.71 | Bone marrow transplantation in a child with Wiskott-Aldrich syndrome latently infected with acyclovir-resistant (ACV(r)) herpes simplex virus type 1: emergence of foscarnet-resistant virus originating from the ACV(r) virus. ( De Clercq, E; Kato, S; Kurane, I; Maeda, A; Morikawa, S; Niikura, M; Saijo, M; Suzutani, T; Yabe, H; Yasuda, Y, 2002) |
| "The influence of sodium lauryl sulfate (SLS) on the efficacies of gel formulations of foscarnet against herpes simplex virus type 1 (HSV-1) cutaneous lesions and on the establishment and reactivation of latent virus has been evaluated in a murine model of orofacial infection." | 3.71 | Efficacies of gel formulations containing foscarnet, alone or combined with sodium lauryl sulfate, against establishment and reactivation of latent herpes simplex virus type 1. ( Bergeron, MG; Désormeaux, A; Lamontagne, J; Piret, J, 2001) |
| "Over an eight-month period from October 1997 to May 1998, four patients who had received bone marrow transplant (BMT) from unrelated donor presented with severe mucosal cutaneous infections involving acyclovir resistant herpes simplex virus 1 (HSV-1)." | 3.71 | Infection due to acyclovir resistant herpes simplex virus in patients undergoing allogeneic hematopoietic stem cell transplantation. ( Bordigoni, P; Carret, AS; Corsaro, D; Dauendorffer, JN; Edert, D; Le Faou, A; Venard, V, 2001) |
| "A leukemic child developed recurrent herpes simplex virus lesions shortly after receiving a bone marrow transplant and while taking acyclovir." | 3.71 | Successful treatment of foscarnet-resistant herpes simplex stomatitis with intravenous cidofovir in a child. ( Bryant, P; Carapetis, J; Curtis, N; Sasadeusz, J; Waters, K, 2001) |
| "Genotypic analysis of herpes simplex virus (HSV) DNA extracted from clinical specimens from a case of fatal disseminated neonatal HSV demonstrated that an infant developed an acyclovir-resistant HSV containing a mutation in the HSV thymidine kinase gene during the first seven days of acyclovir therapy." | 3.71 | Development of acyclovir-resistant herpes simplex virus early during the treatment of herpes neonatorum. ( Leary, JJ; Levin, MJ; Sarisky, RT; Weinberg, A, 2001) |
| "An unusually high incidence of acyclovir- and foscarnet-resistant herpes simplex virus (HSV) infection was noted after lymphocyte-depleted blood hematopoietic progenitor cell (HPC) transplantation from HLA-haploidentical family donors." | 3.71 | Development of drug-resistant herpes simplex virus infection after haploidentical hematopoietic progenitor cell transplantation. ( Allen, A; Bucur, S; Caliendo, AM; Cherry, J; Hutcherson, D; Langston, AA; Lonial, S; Redei, I; Somani, J; Waller, EK, 2002) |
| "The objective of this study was to investigate the prevalence of resistance of herpes simplex virus to acyclovir and foscarnet." | 3.71 | [In vitro susceptibility study of herpes simplex virus to acyclovir and foscarnet. Are routine susceptibility studies necessary?]. ( Cañizares, A; Guerrero, A; Hellín, T; Losada, I; Martí-Belda, P, 2002) |
| "Sequential herpes simplex virus (HSV) isolates from AIDS patients receiving foscarnet therapy were evaluated for susceptibility to adefovir." | 3.71 | Herpes simplex virus isolates with reduced adefovir susceptibility selected in vivo by foscarnet therapy. ( Bestman-Smith, J; Boivin, G, 2002) |
| "Seventeen AIDS patients with cytomegalovirus (CMV), herpes simplex virus (HSV), varicella-zoster virus (VZV) infection, Kaposi's sarcoma (KS), or a combination of these were treated with foscarnet." | 3.70 | Foscarnet decreases HIV-1 plasma load. ( Barbeau, P; Breilh, D; Denisi, R; Devianne-Garrigue, I; Dupon, M; Fleury, HJ; Leng, B; Pellegrin, I; Pellegrin, JL; Ragnaud, JM, 1998) |
| "Herpes simplex virus (HSV) isolates were characterized from 8 AIDS patients in whom acyclovir and foscarnet therapy sequentially failed." | 3.70 | Characterization of the DNA polymerase and thymidine kinase genesof herpes simplex virus isolates from AIDS patients in whom acyclovirand foscarnet therapy sequentially failed. ( Boivin, G; Schmit, I, 1999) |
| "The efficacy of intravitreal foscarnet injections was evaluated in a rabbit model of Herpes simplex virus type-1 (HSV-1) retinitis." | 3.70 | Reducing chorioretinal viral counts with intravitreal foscarnet injections in a rabbit model of Herpes simplex virus type-1 retinitis. ( Beauchamp, D; Bergeron, MG; Delorme, C; Désormeaux, A; Gourde, P; Morin, NJ; Omar, RF; Rousseau, A; Tremblay, MJ, 1999) |
| "The topical efficacies of foscarnet and acyclovir incorporated into a polyoxypropylene-polyoxyethylene polymer were evaluated and compared to that of 5% acyclovir ointment (Zovirax) by use of a murine model of cutaneous herpes simplex virus type 1 infection." | 3.70 | Efficacies of topical formulations of foscarnet and acyclovir and of 5-percent acyclovir ointment (Zovirax) in a murine model of cutaneous herpes simplex virus type 1 infection. ( Bergeron, MG; Désormeaux, A; Gourde, P; Juhász, J; Piret, J, 2000) |
| "The influence of sodium lauryl sulfate (SLS) on the efficacies of topical gel formulations of foscarnet against herpes simplex virus type 1 (HSV-1) cutaneous infection has been evaluated in mice." | 3.70 | Sodium lauryl sulfate increases the efficacy of a topical formulation of foscarnet against herpes simplex virus type 1 cutaneous lesions in mice. ( Bergeron, MG; Cormier, H; Désormeaux, A; Gourde, P; Juhász, J; Lamontagne, J; Piret, J, 2000) |
| "Fourteen cases of severe acyclovir-resistant herpes simplex virus type 1 (HSV-1) infection, 7 of which showed resistance to foscarnet, were diagnosed among 196 allogeneic stem cell transplant recipients within a 29-month period." | 3.70 | Resistant herpes simplex virus type 1 infection: an emerging concern after allogeneic stem cell transplantation. ( Aymard, M; Chen, Y; Devergie, A; Espérou, H; Garderet, L; Garrait, V; Gluckman, E; Hocqueloux, L; Leleu, G; Molina, JM; Morfin, F; Morinet, F; Ribaud, P; Rocha, V; Scieux, C; Sélimi, F; Socié, G; Thouvenot, D, 2000) |
| " One patient with AIDS suffered from a perineal lesion due to infection with herpes simplex virus type 2 (HSV-2) and did not respond to acyclovir and was intolerant of foscarnet." | 3.69 | Successful treatment of progressive mucocutaneous infection due to acyclovir- and foscarnet-resistant herpes simplex virus with (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC). ( Andrei, G; Balzarini, J; Clumeck, N; De Clercq, E; Gérard, M; Hedderman, A; Sadzot-Delvaux, C; Silverman, A; Snoeck, R; Tricot, G, 1994) |
| "A rapid screening test for antiviral susceptibility to acyclovir and foscarnet was evaluated in 320 herpes simplex virus (HSV) isolates from 197 patients." | 3.69 | A rapid screen test for in vitro susceptibility of clinical herpes simplex virus isolates. ( Elbeik, T; Mills, J; Safrin, S, 1994) |
| "We established a quantitative flow cytometric method for determination of herpes simplex virus type 1 (HSV-1) susceptibility to acyclovir (ACV), ganciclovir, and foscarnet in vitro." | 3.69 | Flow cytometric analysis of herpes simplex virus type 1 susceptibility to acyclovir, ganciclovir, and foscarnet. ( Hampl, W; Hartmann, A; Mertens, T; Michel, D; Pavić, I; Schleyer, I; Zimmermann, A, 1997) |
| "Foscavir (foscarnet sodium) has been approved by the Food and Drug Administration (FDA) for use in combination with Cytovene (intravenous ganciclovir) for the treatment of recurrent AIDS-related cytomegalovirus retinitis that has been treated previously with either drug alone." | 3.69 | Foscavir receives new indication. ( , 1997) |
| "A 41-year-old recipient of matched unrelated BMT acquired a severe mucocutaneous herpes simplex virus (HSV) type I infection during acyclovir prophylaxis." | 3.68 | Successful foscarnet therapy for acyclovir-resistant mucocutaneous infection with herpes simplex virus in a recipient of allogeneic BMT. ( Cornelissen, JJ; de Gast, GC; Dekker, AW; Lepoutre, J; Rozenberg-Arska, M; Smit, J; Verdonck, LF, 1993) |
| "Three AIDS patients with severe cutaneous herpes simplex virus (HSV) infection refractory to therapy with acyclovir and foscarnet (2 patients) were treated with a topical preparation of trifluorothymidine (TFT) and interferon-alpha." | 3.68 | Clinical effects and in vitro studies of trifluorothymidine combined with interferon-alpha for treatment of drug-resistant and -sensitive herpes simplex virus infections. ( Birch, CJ; Doherty, R; Hayes, K; Lucas, CR; Mijch, A; Tachedjian, G; Tyssen, DP, 1992) |
| "Resistance of herpes simplex virus to acyclovir is a problem of growing clinical importance." | 3.68 | Heterogeneity of a herpes simplex virus clinical isolate exhibiting resistance to acyclovir and foscarnet. ( Coen, DM; Hicks, KA; Pelosi, E; Sacks, SL, 1992) |
| "Foscarnet (trisodium phosphonoformate), an investigational pyrophosphate analog increasingly used to treat refractory cytomegalovirus retinitis and mucocutaneous herpes simplex virus infections in immunocompromised patients, has been reported to cause abnormalities in serum calcium and phosphate, including cases of fatal hypocalcemia." | 3.68 | Foscarnet-induced hypocalcemia and effects of foscarnet on calcium metabolism. ( Aweeka, FT; Causey, DM; Gambertoglio, JG; Jacobson, MA; Portale, AA, 1991) |
| "Mucocutaneous herpes simplex virus (HSV) infections that are resistant to therapy with acyclovir have been recognized with increasing frequency in patients with the acquired immunodeficiency syndrome, although alternative therapies in this setting have not been widely studied." | 3.68 | Foscarnet therapy for acyclovir-resistant mucocutaneous herpes simplex virus infection in 26 AIDS patients: preliminary data. ( Assaykeen, T; Follansbee, S; Mills, J; Safrin, S, 1990) |
| "Three marrow transplant patients developed pneumonia due to acyclovir-resistant thymidine-kinase-deficient herpes simplex virus (HSV) type 1." | 3.68 | Acyclovir-resistant herpes simplex virus causing pneumonia after marrow transplantation. ( Ellis, MN; Hackman, RC; Ljungman, P; Meyers, JD; Shepp, DH, 1990) |
| "Acyclovir (ACV)-resistant herpes simplex virus type 2 (HSV-2) was isolated from a patient with acquired immunodeficiency syndrome after long-term but intermittent ACV therapy." | 3.68 | Altered sensitivity to antiviral drugs of herpes simplex virus isolates from a patient with the acquired immunodeficiency syndrome. ( Birch, CJ; Doherty, RR; Gust, ID; Hayes, K; Tachedjian, G, 1990) |
| "To determine whether trisodium phosphonoformate (foscarnet) is efficacious in treating severe mucocutaneous disease due to acyclovir-resistant herpes simplex virus type-2 (HSV-2) infection in patients with the acquired immunodeficiency syndrome (AIDS)." | 3.67 | Foscarnet therapy for severe acyclovir-resistant herpes simplex virus type-2 infections in patients with the acquired immunodeficiency syndrome (AIDS). An uncontrolled trial. ( Drennan, DP; Erlich, KS; Follansbee, SE; Gooze, L; Jacobson, MA; Koehler, JE; Mills, J; Safrin, S, 1989) |
| "The influence of (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU), caffeic acid oxidation product (KOP), and trisodiumphosphonoformate (TPF) on the course of the primary cutaneous herpes simplex virus infection was investigated by means of a guinea pig test model." | 3.67 | Therapeutic effect of (E)-5-(2-bromovinyl)-2'-deoxyuridine, caffeic acid oxidation product, and trisodiumphosphonoformate on cutaneous herpes simplex virus type 1 infection in guinea pigs. ( Helbig, B; Herrmann, G; Klöcking, R; Sauerbrei, A; Wicht, N; Wiedemann, U; Wutzler, P, 1987) |
| "The herpesvirus DNA polymerase inhibitor foscarnet, applied topically, and the anti-herpesvirus guanosine analogue buciclovir, given orally, decreased virus replication and disease development in primary skin infections of mice caused by herpes simplex virus type 1 (HSV-1)." | 3.67 | Limited efficacy of inhibitors of herpes simplex virus DNA synthesis in murine models of recrudescent disease. ( Datema, R; Ericson, AC; Kristofferson, A; Sohl-Akerlund, A, 1988) |
| "The sensitivity of different herpes simplex virus type 2 (HSV-2) strains to inhibition by 5-vinyl-1-beta-D-arabinofuranosyluracil (VaraU) was evaluated in comparison to 9-(2-hydroxyethoxymethyl)guanine (ACV; acyclovir) and trisodiumphosphonoformate (Na3PFA; foscarnet), using a plaque inhibition assay in primary rabbit testes (PRT) cells as well as in human embryonic lung fibroblast (HELF) cell cultures." | 3.67 | Efficacy of 5-vinyl-1-beta-D-arabinofuranosyluracil (VaraU) against herpes simplex virus type 2 strains in cell cultures and against experimental herpes encephalitis in mice: comparison with acyclovir and foscarnet. ( Herrmann, G; Reefschläger, J; Thiel, KD; Wutzler, P, 1987) |
| "Topical foscarnet (PFA) and acyclovir (ACV) were compared in the dorsal cutaneous guinea pig model of herpes simplex virus type 1 infection." | 3.67 | Comparison of foscarnet cream, acyclovir cream, and acyclovir ointment in the topical treatment of experimental cutaneous herpes simplex virus type 1 infection. ( Freeman, DJ; Sheth, NV; Spruance, SL, 1986) |
| "Methoxymethyldeoxyuridine (MMUdR) when used in combination with either trifluorothymidine (F3TdR) or phosphonoformate (PFA) showed synergistic activity against herpes simplex virus type 1 and type 2 (HSV-1 and HSV-2) in vitro, whereas MMUdR and acycloguanosine (ACG) combination was antagonistic against herpes viruses." | 3.67 | Combination chemotherapy: interaction of 5-methoxymethyldeoxyuridine with trifluorothymidine, phosphonoformate and acycloguanosine against herpes simplex viruses. ( Ayisi, NK; Babiuk, LA; Gupta, SV, 1985) |
| "The efficiency of (E)-5-(2-bromovinyl)- and 5-vinyl-1-beta-D-arabinofuranosyluracil (BrVaraU, VaraU) as inhibitors of three herpes simplex virus type 1 (HSV-1) strains was assessed in comparison to (E)-5-(2-bromovinyl)-2'-deoxyuridine (BrVUdR), 9-(2-hydroxyethoxymethyl)guanine (ACV), and trisodium phosphonoformate (Na3PFA) using a plaque assay in human embryonic lung fibroblast (HELF) cell cultures." | 3.67 | Treatment of experimental herpes simplex virus type 1 encephalitis in mice with (E)-5-(2-bromovinyl)- and 5-vinyl-1-beta-D-arabinofuranosyluracil: comparison with bromovinyl-deoxyuridine and acyclovir. ( Herrmann, G; Reefschläger, J; Thiel, KD; Wutzler, P, 1986) |
| "The therapeutic effects of topically applied foscarnet sodium and acyclovir on cutaneous infections due to herpes simplex virus type 1 (HSV-1) were studied in guinea pigs." | 3.66 | Therapeutic effects of foscarnet sodium and acyclovir on cutaneous infections due to herpes simplex virus type 1 in guinea pigs. ( Alenius, S; Berg, M; Broberg, F; Eklind, K; Lindborg, B; Oberg, B, 1982) |
| " These questions concern appropriate routes of administration for antiviral compounds, optimal dosage regimens, risks of long-term prophylaxis, and the emergence of resistant organisms." | 2.66 | Antiviral chemotherapy and chemoprophylaxis. ( Dolin, R, 1985) |
| " The dosage of foscarnet should be 40 milligrams per kilogram three times per day or 60 milligrams per kilogram twice daily." | 2.42 | Management of acyclovir-resistant herpes simplex virus. ( Chilukuri, S; Rosen, T, 2003) |
| " Myelosuppression may be further exacerbated in AIDS patients by such other agents as zidovudine or trimethoprim/sulfamethoxazole, often necessitating dosage reductions or discontinuation of these agents in patients receiving ganciclovir." | 2.38 | Foscarnet sodium. ( Baltz, JK; Minor, JR, 1991) |
| "Acyclovir is a prototype of this improved process." | 2.37 | Promising new antiviral drugs. ( Bryson, YJ, 1988) |
| "The mechanism of recurrence is yet not fully elucidated and therapy still remains a problem." | 2.36 | [Herpes simplex]. ( Fanta, D, 1981) |
| "Genital herpes is an important cofactor for acquisition of human immunodeficiency virus (HIV) infection, and effective prophylaxis is a helpful strategy to halt both HIV and herpes simplex virus (HSV) transmission." | 1.48 | The Anti-Human Immunodeficiency Virus Drug Tenofovir, a Reverse Transcriptase Inhibitor, Also Targets the Herpes Simplex Virus DNA Polymerase. ( Andrei, G; Gillemot, S; Snoeck, R; Topalis, D, 2018) |
| "Foscarnet was administered for a period of 3 weeks with almost complete healing of the ulcerations." | 1.48 | [Acyclovir-resistant perineal HSV infection revealing chronic lymphoid leukaemia]. ( Bulai Livideanu, C; Casassa, EA; Fortenfant, F; Gaudin, C; Konstantinou, MP; Lamant, L; Mengelle, C; Nicol, P; Paul, C; Viraben, R, 2018) |
| "Imiquimod treatment also appeared to delay the time to recurrence of HSV lesions." | 1.38 | Successful treatment of aciclovir and foscarnet resistant Herpes simplex virus lesions with topical imiquimod in patients infected with human immunodeficiency virus type 1. ( Agut, H; Caumes, E; Challine, D; Deback, C; Lascaux, AS; Lévy, Y; Melica, G, 2012) |
| "Retinal detachment is the main complication." | 1.32 | [Acute retinal necrosis: clinical presentation, treatment, and prognosis in a series of 22 patients]. ( Laroche, L; Larricart, P; Metge, F; Monin, C; Morel, C; Roman, S; Scheer, S, 2004) |
| " Afterwards other drugs have been developed either with a better bioavailability or with an activity against aciclovir-resistant strains." | 1.31 | [Antiretroviral drugs for the treatment and prevention of herpes infections in the year 2000]. ( Malkin, JE, 2002) |
| "Foscarnet is a non-thymidine kinase-dependent agent, but the emergence of ACV and foscarnet-resistant HSV requires a new therapeutic approach." | 1.31 | Treatment of an acyclovir and foscarnet-resistant herpes simplex virus infection with cidofovir in a child after an unrelated bone marrow transplant. ( Blot, N; Dehesdin, D; Janvresse, C; Schneider, P; Tron, P; Vannier, JP; Young, P, 2000) |
| "Retinitis was clinically graded by indirect ophthalmoscopy, and the retinitis scores were compared across the treatment and control groups." | 1.30 | Treatment of herpes retinitis in an animal model with a sustained delivery antiviral drug, liposomal 1-O-octadecyl-SN-glycerol-3-phosphonoformate. ( Bergeron-Lynn, G; Chaidhawangul, S; Cheng, L; Freeman, WR; Gardner, MF; Hostetler, KY; Mach-Hofacre, B; Mueller, AJ; Ozerdem, U; Severson, GM, 1999) |
| "The acute lumbosacral polyradiculomyelitis (ALP) in patients with AIDS is a well defined nosologic entity and classically associated to CMV infection." | 1.30 | [Lumbosacral polyradiculomyelitis caused by herpes simplex virus (HSV) in a patient with AIDS]. ( Correa-Nazco, VJ; González, M; Laynez, P; Linares, M; Martínez, A; Miguélez, M, 1999) |
| "Virus isolates from four AIDS patients and one bone marrow transplant recipient were examined for their sensitivity for the antiviral compounds used by means of plaque reduction assay." | 1.28 | [Acyclovir-resistant herpes simplex virus infections in immunocompromised patients]. ( Frissen, PH; Jansen, CL; Maris-Tegeler, WG; van der Noordaa, J; Weiland, HT; Wertheim-van Dillen, PM, 1992) |
| " The dosage of Foscarnet was increased during the study." | 1.27 | Clinical experiences with phosphonoformate (foscarnet) treatment of viral diseases following renal transplantation. ( Ahlmén, J; Brynger, H; Lycke, E; Wijnween, AC, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 26 (18.84) | 18.7374 |
| 1990's | 55 (39.86) | 18.2507 |
| 2000's | 26 (18.84) | 29.6817 |
| 2010's | 21 (15.22) | 24.3611 |
| 2020's | 10 (7.25) | 2.80 |
| Authors | Studies |
|---|---|
| Griengl, H | 1 |
| Hayden, W | 1 |
| Penn, G | 1 |
| De Clercq, E | 4 |
| Rosenwirth, B | 1 |
| Hopkins, CR | 1 |
| Lowe, N | 1 |
| Lee, G | 1 |
| Saunsbury, T | 1 |
| Harte, M | 1 |
| Ion, D | 1 |
| Khellaf, L | 1 |
| Bouscarat, F | 1 |
| Burrel, S | 4 |
| Fidouh, N | 1 |
| Hachon, L | 1 |
| Bucau, M | 1 |
| Lariven, S | 1 |
| Boutolleau, D | 4 |
| Joly, V | 1 |
| Ghosn, J | 1 |
| Le Pluart, D | 1 |
| Thy, M | 1 |
| Schalkwijk, HH | 1 |
| Gillemot, S | 2 |
| Reynders, M | 1 |
| Selleslag, D | 1 |
| Andrei, G | 4 |
| Snoeck, R | 4 |
| Kotton, BD | 1 |
| Kotton, CN | 1 |
| Giorgi, J | 1 |
| Simon, B | 1 |
| Destras, G | 1 |
| Semanas, Q | 1 |
| Ginevra, C | 1 |
| Boyer, T | 1 |
| Regue, H | 1 |
| Billaud, G | 1 |
| Ducastelle, S | 1 |
| Ader, F | 1 |
| Morfin, F | 4 |
| Josset, L | 1 |
| Frobert, E | 2 |
| Glasgow, HL | 1 |
| Zhu, H | 1 |
| Xie, H | 1 |
| Kenkel, EJ | 1 |
| Lee, C | 1 |
| Huang, ML | 1 |
| Greninger, AL | 1 |
| Hafidi, M | 1 |
| Janin-Manificat, H | 1 |
| Denis, P | 1 |
| Charleux, B | 1 |
| Rabilloud, M | 1 |
| Boibieux, A | 1 |
| Burillon, C | 1 |
| Kodjikian, L | 1 |
| Heidenreich, D | 1 |
| Kreil, S | 1 |
| Mueller, N | 1 |
| Jawhar, M | 1 |
| Nolte, F | 1 |
| Hofmann, WK | 1 |
| Klein, SA | 1 |
| Topalis, D | 2 |
| Rose, R | 1 |
| Brunnemann, AK | 1 |
| Baukmann, S | 1 |
| Bühler, S | 1 |
| Fickenscher, H | 1 |
| Sauerbrei, A | 5 |
| Zell, R | 3 |
| Krumbholz, A | 1 |
| Gonzales Zamora, JA | 1 |
| Espinoza, LA | 1 |
| Casassa, EA | 1 |
| Nicol, P | 1 |
| Viraben, R | 1 |
| Gaudin, C | 1 |
| Bulai Livideanu, C | 1 |
| Mengelle, C | 1 |
| Lamant, L | 1 |
| Fortenfant, F | 1 |
| Paul, C | 1 |
| Konstantinou, MP | 1 |
| Ikawa, Y | 1 |
| Fujiki, T | 1 |
| Nishimura, R | 1 |
| Noguchi, K | 1 |
| Koshino, E | 1 |
| Fujiki, A | 1 |
| Fukuda, M | 1 |
| Kuroda, R | 1 |
| Mase, S | 1 |
| Araki, R | 1 |
| Maeba, H | 1 |
| Shiraki, K | 1 |
| Yachie, A | 1 |
| Ong, SS | 1 |
| Postel, EA | 1 |
| Aime, C | 1 |
| Hermet, L | 1 |
| Ait-Arkoub, Z | 1 |
| Agut, H | 3 |
| Seang, S | 1 |
| Regnier, S | 1 |
| Epelboin, L | 1 |
| Voujon, D | 1 |
| Valantin, MA | 1 |
| Katlama, C | 1 |
| Caumes, E | 2 |
| Dokey, AT | 1 |
| Haug, SJ | 1 |
| McDonald, HR | 1 |
| Cunningham, ET | 1 |
| Lujan, BJ | 1 |
| Fu, AD | 1 |
| Jumper, JM | 1 |
| Weissman, HM | 1 |
| Biousse, V | 1 |
| Schechter, MC | 1 |
| Del Rio, C | 1 |
| Yeh, S | 2 |
| Schmidt, S | 1 |
| Bohn-Wippert, K | 1 |
| Schlattmann, P | 1 |
| Voigt, S | 1 |
| Hofmann, J | 2 |
| Edelmann, A | 1 |
| Kühl, JS | 1 |
| Stryjewski, TP | 1 |
| Scott, NL | 1 |
| Barshak, MB | 1 |
| Tobin, EH | 1 |
| Mali, JO | 1 |
| Young, LH | 1 |
| Foster, CS | 1 |
| Kim, IK | 1 |
| Durand, ML | 1 |
| Bergmann, M | 1 |
| Beer, R | 1 |
| Kofler, M | 1 |
| Helbok, R | 1 |
| Pfausler, B | 1 |
| Schmutzhard, E | 1 |
| Schoenberger, SD | 1 |
| Kim, SJ | 1 |
| Thorne, JE | 1 |
| Mruthyunjaya, P | 1 |
| Bakri, SJ | 1 |
| Ehlers, JP | 1 |
| Wong, R | 1 |
| Pavesio, CE | 1 |
| Laidlaw, DA | 1 |
| Williamson, TH | 1 |
| Graham, EM | 1 |
| Stanford, MR | 1 |
| Meghpara, B | 1 |
| Sulkowski, G | 1 |
| Kesen, MR | 1 |
| Tessler, HH | 1 |
| Goldstein, DA | 1 |
| Moses, SE | 1 |
| Osborne, W | 1 |
| Valappil, M | 1 |
| Collin, M | 1 |
| Lee, D | 1 |
| Waugh, S | 1 |
| Jackson, G | 1 |
| Parry, CM | 1 |
| Crowley, B | 1 |
| Bohn, K | 1 |
| Heim, A | 1 |
| Weissbrich, B | 1 |
| Schnitzler, P | 1 |
| Hoffmann, D | 1 |
| Jahn, G | 1 |
| Wutzler, P | 5 |
| Hamprecht, K | 1 |
| Lascaux, AS | 1 |
| Deback, C | 1 |
| Melica, G | 1 |
| Challine, D | 1 |
| Lévy, Y | 1 |
| Muluneh, B | 1 |
| Dean, A | 1 |
| Armistead, P | 1 |
| Khan, T | 1 |
| Saijo, M | 1 |
| Yasuda, Y | 1 |
| Yabe, H | 1 |
| Kato, S | 1 |
| Suzutani, T | 1 |
| Niikura, M | 1 |
| Maeda, A | 1 |
| Kurane, I | 1 |
| Morikawa, S | 1 |
| Brown, TJ | 1 |
| McCrary, M | 1 |
| Tyring, SK | 1 |
| Gain, P | 1 |
| Chiquet, C | 1 |
| Thuret, G | 1 |
| Drouet, E | 1 |
| Antoine, JC | 1 |
| Malkin, JE | 1 |
| Thouvenot, D | 3 |
| Klammer, M | 1 |
| Kuhn, A | 1 |
| Ruzicka, T | 1 |
| Stege, H | 1 |
| Chilukuri, S | 1 |
| Rosen, T | 1 |
| Inaba, H | 1 |
| Rabah, R | 1 |
| Meert, KL | 1 |
| BhamBhani, K | 1 |
| Morel, C | 1 |
| Metge, F | 1 |
| Roman, S | 1 |
| Scheer, S | 1 |
| Larricart, P | 1 |
| Monin, C | 1 |
| Laroche, L | 1 |
| Tran, TH | 1 |
| Stanescu, D | 1 |
| Caspers-Velu, L | 1 |
| Rozenberg, F | 1 |
| Liesnard, C | 1 |
| Gaudric, A | 1 |
| Lehoang, P | 1 |
| Bodaghi, B | 1 |
| Greco, A | 1 |
| Callé, A | 1 |
| Cayre, M | 1 |
| Kindbeiter, K | 1 |
| Martin, L | 1 |
| Levillain, O | 1 |
| Diaz, JJ | 1 |
| Khurana, RN | 1 |
| Charonis, A | 1 |
| Samuel, MA | 1 |
| Gupta, A | 1 |
| Tawansy, KA | 1 |
| Fiten, P | 1 |
| Froeyen, M | 1 |
| Opdenakker, G | 1 |
| Ganner, A | 1 |
| Lee, YM | 1 |
| Busche, C | 1 |
| Schmitt-Graeff, A | 1 |
| Encke, J | 1 |
| Walz, G | 1 |
| Gerke, P | 1 |
| Poryo, A | 1 |
| Wigand, R | 2 |
| Burkhardt, U | 1 |
| Svennerholm, B | 2 |
| Ziegler, R | 1 |
| Lycke, E | 3 |
| Blohmé, I | 1 |
| Ahlmén, J | 2 |
| Jeansson, S | 1 |
| Ranch, T | 1 |
| Brynger, H | 2 |
| Alenius, S | 2 |
| Vahlne, A | 1 |
| Berg, M | 1 |
| Broberg, F | 1 |
| Eklind, K | 1 |
| Lindborg, B | 1 |
| Oberg, B | 1 |
| Fanta, D | 1 |
| Klein, RJ | 1 |
| Jones, TJ | 1 |
| Paul, R | 1 |
| Gérard, M | 1 |
| Silverman, A | 1 |
| Hedderman, A | 1 |
| Balzarini, J | 1 |
| Sadzot-Delvaux, C | 1 |
| Tricot, G | 1 |
| Clumeck, N | 1 |
| Safrin, S | 7 |
| Elbeik, T | 2 |
| Phan, L | 1 |
| Robinson, D | 1 |
| Rush, J | 1 |
| Elbaggari, A | 1 |
| Mills, J | 5 |
| Balfour, HH | 1 |
| Benson, C | 1 |
| Braun, J | 1 |
| Cassens, B | 1 |
| Erice, A | 1 |
| Friedman-Kien, A | 1 |
| Klein, T | 2 |
| Polsky, B | 1 |
| Nyquist, AC | 1 |
| Rotbart, HA | 1 |
| Cotton, M | 1 |
| Robinson, C | 1 |
| Weinberg, A | 2 |
| Hayward, AR | 1 |
| Berens, RL | 1 |
| Levin, MJ | 2 |
| Baumann, R | 1 |
| Wunderli, W | 2 |
| Riess, C | 1 |
| Vogt, M | 1 |
| Verdonck, LF | 1 |
| Cornelissen, JJ | 1 |
| Smit, J | 1 |
| Lepoutre, J | 1 |
| de Gast, GC | 1 |
| Dekker, AW | 1 |
| Rozenberg-Arska, M | 1 |
| Scieux, C | 3 |
| Bianchi, A | 1 |
| Naik, HR | 1 |
| Siddique, N | 1 |
| Chandrasekar, PH | 1 |
| Palacios, E | 1 |
| Leahy, BJ | 1 |
| Smith, NA | 1 |
| Wood, C | 1 |
| Asboe, D | 1 |
| Bingham, JS | 1 |
| Segal, BH | 1 |
| Engler, HD | 1 |
| Little, R | 1 |
| Wilson, WH | 1 |
| Freifeld, AG | 1 |
| Chanock, SJ | 1 |
| Lalezari, J | 1 |
| Schacker, T | 1 |
| Feinberg, J | 1 |
| Gathe, J | 1 |
| Lee, S | 1 |
| Cheung, T | 1 |
| Kramer, F | 1 |
| Kessler, H | 1 |
| Corey, L | 1 |
| Drew, WL | 1 |
| Boggs, J | 1 |
| McGuire, B | 1 |
| Jaffe, HS | 1 |
| Pavić, I | 1 |
| Hartmann, A | 1 |
| Zimmermann, A | 1 |
| Michel, D | 1 |
| Hampl, W | 1 |
| Schleyer, I | 1 |
| Mertens, T | 1 |
| LoPresti, AE | 1 |
| Levine, JF | 1 |
| Munk, GB | 1 |
| Tai, CY | 1 |
| Mendel, DB | 1 |
| Read, RC | 1 |
| Vilar, FJ | 1 |
| Smith, TL | 1 |
| Devianne-Garrigue, I | 1 |
| Pellegrin, I | 1 |
| Denisi, R | 1 |
| Dupon, M | 1 |
| Ragnaud, JM | 1 |
| Barbeau, P | 1 |
| Breilh, D | 1 |
| Leng, B | 1 |
| Fleury, HJ | 1 |
| Pellegrin, JL | 1 |
| Awan, AR | 2 |
| Harmenberg, J | 3 |
| Kristofferson, A | 2 |
| Field, HJ | 2 |
| Lateef, F | 1 |
| Don, PC | 1 |
| Kaufmann, M | 1 |
| White, SM | 1 |
| Weinberg, JM | 1 |
| Pechère, M | 1 |
| Trellu-Toutous, L | 1 |
| Harms, M | 1 |
| Saura, JH | 1 |
| Krischer, J | 1 |
| Flink, O | 1 |
| Justman, J | 1 |
| Zabezhanskaya, M | 1 |
| Schmit, I | 1 |
| Boivin, G | 2 |
| Javaly, K | 1 |
| Wohlfeiler, M | 1 |
| Kalayjian, R | 1 |
| Bryson, Y | 1 |
| Grafford, K | 1 |
| Martin-Munley, S | 1 |
| Hardy, WD | 2 |
| Cheng, L | 1 |
| Hostetler, KY | 1 |
| Chaidhawangul, S | 1 |
| Gardner, MF | 1 |
| Ozerdem, U | 1 |
| Bergeron-Lynn, G | 1 |
| Mach-Hofacre, B | 1 |
| Mueller, AJ | 1 |
| Severson, GM | 1 |
| Freeman, WR | 1 |
| Miguélez, M | 1 |
| Correa-Nazco, VJ | 1 |
| Linares, M | 1 |
| Laynez, P | 1 |
| González, M | 1 |
| Martínez, A | 1 |
| Morin, NJ | 1 |
| Delorme, C | 1 |
| Gourde, P | 3 |
| Omar, RF | 1 |
| Désormeaux, A | 4 |
| Tremblay, MJ | 1 |
| Beauchamp, D | 1 |
| Rousseau, A | 1 |
| Bergeron, MG | 4 |
| Cotarelo, M | 1 |
| Catalán, P | 1 |
| Sánchez-Carrillo, C | 1 |
| Menasalvas, A | 1 |
| Cercenado, E | 1 |
| Tenorio, A | 1 |
| Bouza, E | 1 |
| Piret, J | 3 |
| Juhász, J | 2 |
| Cormier, H | 1 |
| Lamontagne, J | 2 |
| Chen, Y | 1 |
| Garrait, V | 1 |
| Socié, G | 1 |
| Rocha, V | 1 |
| Molina, JM | 2 |
| Hocqueloux, L | 1 |
| Garderet, L | 1 |
| Espérou, H | 1 |
| Sélimi, F | 1 |
| Devergie, A | 1 |
| Leleu, G | 1 |
| Aymard, M | 1 |
| Morinet, F | 2 |
| Gluckman, E | 1 |
| Ribaud, P | 1 |
| Blot, N | 1 |
| Schneider, P | 1 |
| Young, P | 1 |
| Janvresse, C | 1 |
| Dehesdin, D | 1 |
| Tron, P | 1 |
| Vannier, JP | 1 |
| Venard, V | 1 |
| Dauendorffer, JN | 1 |
| Carret, AS | 1 |
| Corsaro, D | 1 |
| Edert, D | 1 |
| Bordigoni, P | 1 |
| Le Faou, A | 1 |
| Bryant, P | 1 |
| Sasadeusz, J | 1 |
| Carapetis, J | 1 |
| Waters, K | 1 |
| Curtis, N | 1 |
| Leary, JJ | 1 |
| Sarisky, RT | 1 |
| Arnulf, B | 1 |
| Chebbi, F | 1 |
| Lefrere, F | 1 |
| Ait Arkoub, Z | 1 |
| Varet, B | 1 |
| Fillet, AM | 1 |
| Langston, AA | 1 |
| Redei, I | 1 |
| Caliendo, AM | 1 |
| Somani, J | 1 |
| Hutcherson, D | 1 |
| Lonial, S | 1 |
| Bucur, S | 1 |
| Cherry, J | 1 |
| Allen, A | 1 |
| Waller, EK | 1 |
| Losada, I | 1 |
| Cañizares, A | 1 |
| Hellín, T | 1 |
| Martí-Belda, P | 1 |
| Guerrero, A | 1 |
| Bestman-Smith, J | 1 |
| Masur, H | 1 |
| Jansen, CL | 1 |
| Maris-Tegeler, WG | 1 |
| Wertheim-van Dillen, PM | 1 |
| Frissen, PH | 2 |
| Weiland, HT | 1 |
| van der Noordaa, J | 1 |
| Birch, CJ | 2 |
| Tyssen, DP | 1 |
| Tachedjian, G | 2 |
| Doherty, R | 1 |
| Hayes, K | 2 |
| Mijch, A | 1 |
| Lucas, CR | 1 |
| Cotte, L | 1 |
| Langlois, M | 1 |
| Trepo, C | 1 |
| Yirrell, DL | 2 |
| Rogers, CE | 2 |
| Blyth, WA | 2 |
| Hill, TJ | 2 |
| Pelosi, E | 1 |
| Hicks, KA | 1 |
| Sacks, SL | 1 |
| Coen, DM | 1 |
| David, F | 1 |
| Schnell, L | 1 |
| Gerrier, F | 1 |
| Kateb, M | 1 |
| Modai, J | 1 |
| Moeland, A | 1 |
| Bruun, JN | 1 |
| Arbesfeld, DM | 1 |
| Thomas, I | 1 |
| Jacobson, MA | 2 |
| Gambertoglio, JG | 1 |
| Aweeka, FT | 1 |
| Causey, DM | 1 |
| Portale, AA | 1 |
| Stellbrink, HJ | 1 |
| Albrecht, H | 1 |
| Löning, T | 1 |
| Greten, H | 1 |
| Bevilacqua, F | 1 |
| Marcello, A | 1 |
| Toni, M | 1 |
| Zavattoni, M | 1 |
| Cusini, M | 1 |
| Zerboni, R | 1 |
| Gerna, G | 1 |
| Palù, G | 1 |
| Minor, JR | 1 |
| Baltz, JK | 1 |
| Van Der Pijl, JW | 1 |
| Reiss, P | 1 |
| Hulsebosch, HJ | 1 |
| Van Den Tweel, JG | 1 |
| Lange, JM | 1 |
| Danner, SA | 1 |
| Charmot, G | 1 |
| Ingrand, D | 1 |
| Simon, F | 1 |
| Kernbaum, S | 1 |
| Fegueux, S | 1 |
| De Truchis, P | 1 |
| Coulaud, JP | 1 |
| Assaykeen, T | 1 |
| Follansbee, S | 1 |
| Ljungman, P | 1 |
| Ellis, MN | 1 |
| Hackman, RC | 1 |
| Shepp, DH | 1 |
| Meyers, JD | 1 |
| Doherty, RR | 1 |
| Gust, ID | 1 |
| Bryson, YJ | 1 |
| Erlich, KS | 1 |
| Koehler, JE | 1 |
| Follansbee, SE | 1 |
| Drennan, DP | 2 |
| Gooze, L | 1 |
| MacPhail, LA | 1 |
| Greenspan, D | 1 |
| Schiødt, M | 1 |
| Chatis, PA | 1 |
| Miller, CH | 1 |
| Schrager, LE | 1 |
| Crumpacker, CS | 1 |
| Helbig, B | 1 |
| Klöcking, R | 1 |
| Wicht, N | 1 |
| Wiedemann, U | 1 |
| Herrmann, G | 3 |
| Ericson, AC | 2 |
| Sohl-Akerlund, A | 1 |
| Datema, R | 2 |
| Reefschläger, J | 2 |
| Thiel, KD | 2 |
| Ulbricht, A | 1 |
| Färber, I | 1 |
| Spruance, SL | 1 |
| Freeman, DJ | 1 |
| Sheth, NV | 1 |
| van Genderen, J | 1 |
| Wolthuis, OL | 1 |
| Ariens, AT | 1 |
| Dolin, R | 1 |
| Ayisi, NK | 1 |
| Gupta, SV | 1 |
| Babiuk, LA | 1 |
| Wijnween, AC | 1 |
| Hall, MJ | 1 |
| Abele, G | 1 |
| Wahren, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Open, Multicenter Study of Foscarnet Treatment of Acyclovir-Resistant Herpes Simplex Virus in Patients With the Acquired Immunodeficiency Syndrome and Other Immunodeficiencies[NCT00002272] | 0 participants | Interventional | Completed | ||||
| An Open Study of Foscarnet Treatment of Acyclovir-Resistant Herpes Simplex Virus in Patients With the Acquired Immunodeficiency Syndrome and Other Immunodeficiencies[NCT00002021] | 0 participants | Interventional | Completed | ||||
| A Phase II Dose-Ranging, Open-Labelled Trial of Foscarnet Salvage Therapy for AIDS Patients With Sight-Threatening CMV Retinitis Who Cannot Be Treated With Ganciclovir Due To Myelosuppression or Treatment Failure[NCT00000691] | Phase 2 | 156 participants | Interventional | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
15 reviews available for foscarnet and Herpes Simplex Virus Infection
| Article | Year |
|---|---|
Resistant herpes simplex virus infections - who, when, and what's new?
Topics: Acyclovir; Antiviral Agents; Cytosine; Foscarnet; Herpes Simplex; Herpesviridae Infections; Humans; | 2022 |
Bilateral central retinal artery occlusion associated with herpes simplex virus-associated acute retinal necrosis and meningitis: case report and literature review.
Topics: Antibodies, Viral; Antiviral Agents; Aqueous Humor; DNA, Viral; Drug Therapy, Combination; Eye Infec | 2015 |
Diagnosis and Treatment of Acute Retinal Necrosis: A Report by the American Academy of Ophthalmology.
Topics: Academies and Institutes; Acyclovir; Antiviral Agents; Aqueous Humor; Biomedical Technology; DNA, Vi | 2017 |
Antiviral agents: Non-antiretroviral [correction of Nonantiviral] drugs.
Topics: 2-Aminopurine; Acyclovir; Antiviral Agents; Chickenpox; Cytomegalovirus Infections; Famciclovir; Fos | 2002 |
Herpes simplex virus resistance to antiviral drugs.
Topics: Acyclovir; Antiviral Agents; Cidofovir; Cytosine; DNA-Directed DNA Polymerase; Drug Resistance, Mult | 2003 |
Management of acyclovir-resistant herpes simplex virus.
Topics: Acyclovir; Antiviral Agents; Cidofovir; Cytosine; Drug Resistance, Viral; Foscarnet; Herpes Simplex; | 2003 |
Clinical characteristics of acute HSV-2 retinal necrosis.
Topics: Acyclovir; Adult; Antiviral Agents; Aqueous Humor; Child; DNA, Viral; Drug Therapy, Combination; Eye | 2004 |
[Herpes simplex].
Topics: Adolescent; Adult; Amantadine; Antigens, Viral; Cell Transformation, Viral; Female; Foscarnet; Herpe | 1981 |
Treatment of experimental latent herpes simplex virus infections with acyclovir and other antiviral compounds.
Topics: Acyclovir; Animals; Antiviral Agents; Culture Techniques; Foscarnet; Ganglia; Guanine; Herpes Simple | 1982 |
Management of acyclovir-resistant herpes simplex and varicella-zoster virus infections.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Adult; Algorithms; Drug Resistance, Microbial; Female | 1994 |
Management of acyclovir-resistant herpes simplex and varicella-zoster virus infections.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Adult; Algorithms; Drug Resistance, Microbial; Female | 1994 |
Management of acyclovir-resistant herpes simplex and varicella-zoster virus infections.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Adult; Algorithms; Drug Resistance, Microbial; Female | 1994 |
Management of acyclovir-resistant herpes simplex and varicella-zoster virus infections.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Adult; Algorithms; Drug Resistance, Microbial; Female | 1994 |
[Resistance of herpes simplex viruses to antiviral drugs].
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; AIDS-Related Opportunistic Infections; DNA-Directed D | 1993 |
[Treatment of herpesvirus infections].
Topics: Acyclovir; Antiviral Agents; Cytomegalovirus Infections; Drug Resistance, Microbial; Foscarnet; Ganc | 1991 |
Cutaneous herpes simplex virus infections.
Topics: Acyclovir; Administration, Oral; Antiviral Agents; Diagnosis, Differential; Drug Resistance, Microbi | 1991 |
Foscarnet sodium.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Eye Infections, Vi | 1991 |
Promising new antiviral drugs.
Topics: Acyclovir; Animals; Antiviral Agents; Bromodeoxyuridine; Cytomegalovirus Infections; Foscarnet; Ganc | 1988 |
4 trials available for foscarnet and Herpes Simplex Virus Infection
| Article | Year |
|---|---|
A randomized, double-blind, placebo-controlled trial of cidofovir gel for the treatment of acyclovir-unresponsive mucocutaneous herpes simplex virus infection in patients with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Adult; Animals; Antiviral Agents; Cells, Cultured; Ch | 1997 |
Treatment of mucocutaneous herpes simplex virus infections unresponsive to acyclovir with topical foscarnet cream in AIDS patients: a phase I/II study.
Topics: Acyclovir; Administration, Topical; Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; | 1999 |
Foscarnet treatment of acyclovir-resistant herpes simplex virus infection in patients with acquired immunodeficiency syndrome: preliminary results of a controlled, randomized, regimen-comparative trial.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Antiviral Agents; Drug Resistance, Microbial; Foscarn | 1992 |
Antiviral chemotherapy and chemoprophylaxis.
Topics: Acyclovir; Adult; Aged; Amantadine; Antiviral Agents; Chickenpox; Clinical Trials as Topic; Cytomega | 1985 |
119 other studies available for foscarnet and Herpes Simplex Virus Infection
| Article | Year |
|---|---|
Phosphonoformate and phosphonoacetate derivatives of 5-substituted 2'-deoxyuridines: synthesis and antiviral activity.
Topics: Animals; Antiviral Agents; Bromodeoxyuridine; Cell Line; Chemical Phenomena; Chemistry; Deoxyuridine | 1988 |
Acyclovir-Resistant Cutaneous Herpes Simplex Virus in DOCK8 Deficiency.
Topics: Acyclovir; Antiviral Agents; Child, Preschool; Drug Resistance, Viral; Female; Foscarnet; Guanine Nu | 2021 |
Unusual oral presentation of acyclovir-resistant herpes simplex in an allogeneic haematopoietic stem cell transplant recipient.
Topics: Acyclovir; Adult; Antiviral Agents; Female; Foscarnet; Hematopoietic Stem Cell Transplantation; Herp | 2021 |
Novel mutations in antiviral multiresistant HSV-2 genital lesion: A case report.
Topics: Acyclovir; Antiviral Agents; Cidofovir; DNA-Directed DNA Polymerase; Drug Resistance, Viral; Foscarn | 2022 |
Heterogeneity and viral replication fitness of HSV-1 clinical isolates with mutations in the thymidine kinase and DNA polymerase.
Topics: Acyclovir; Antiviral Agents; Cidofovir; DNA-Directed DNA Polymerase; Drug Resistance, Viral; Foscarn | 2022 |
Novel UL23 and UL30 substitutions in HSV1 and HSV2 viruses related to polymorphism or drug resistance.
Topics: Acyclovir; Antiviral Agents; Drug Resistance, Viral; Foscarnet; Herpes Simplex; Herpesvirus 1, Human | 2023 |
Genotypic testing improves detection of antiviral resistance in human herpes simplex virus.
Topics: Acyclovir; Antiviral Agents; Drug Resistance, Viral; Foscarnet; Genotype; Herpes Simplex; Herpesviru | 2023 |
Acute Retinal Necrosis: Virological Features Using Quantitative Polymerase Chain Reaction, Therapeutic Management, and Clinical Outcomes.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Aqueous Humor; Cytomegalovirus Retinitis; DNA, Vir | 2019 |
Topical Treatment of Acyclovir-Resistant Herpes Simplex Virus Stomatitis after Allogeneic Hematopoietic Cell Transplantation.
Topics: Acyclovir; Administration, Topical; Adult; Aged; Antiviral Agents; Cidofovir; Drug Resistance, Viral | 2020 |
[Herpes simplex virus resistance to antivirals].
Topics: Acyclovir; Antiviral Agents; Foscarnet; Herpes Simplex; Humans; Simplexvirus | 2020 |
Antiviral susceptibility of recombinant Herpes simplex virus 1 strains with specific polymerase amino acid changes.
Topics: Acyclovir; Animals; Antiviral Agents; Chlorocebus aethiops; Cidofovir; DNA-Directed DNA Polymerase; | 2021 |
Verrucous herpes of the finger in a patient with HIV-1 infection.
Topics: Acyclovir; Administration, Intravenous; Administration, Oral; Antiviral Agents; Fingers; Foscarnet; | 2018 |
The Anti-Human Immunodeficiency Virus Drug Tenofovir, a Reverse Transcriptase Inhibitor, Also Targets the Herpes Simplex Virus DNA Polymerase.
Topics: Acyclovir; Amino Acid Substitution; Antiviral Agents; Cells, Cultured; DNA Mutational Analysis; DNA- | 2018 |
[Acyclovir-resistant perineal HSV infection revealing chronic lymphoid leukaemia].
Topics: Acyclovir; Adjuvants, Immunologic; Administration, Cutaneous; Aged, 80 and over; Aminoquinolines; An | 2018 |
Improvement of refractory acyclovir-resistant herpes simplex virus type 1 infection by continuous acyclovir administration.
Topics: Acyclovir; Antiviral Agents; Child; Drug Resistance, Viral; Female; Foscarnet; Hematopoietic Stem Ce | 2019 |
Sudden Unilateral Decrease in Vision in a Healthy Middle-aged Man.
Topics: Antiviral Agents; Eye Infections, Viral; Fluorescein Angiography; Foscarnet; Herpes Simplex; Herpesv | 2018 |
Surveillance of herpes simplex virus resistance to antivirals: a 4-year survey.
Topics: Acyclovir; Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Child; Child, Preschool; Dr | 2013 |
Long-term follow-up of HIV-infected patients once diagnosed with acyclovir-resistant herpes simplex virus infection.
Topics: Acyclovir; Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Cidofovir; Cytosine; Drug | 2014 |
Acute retinal necrosis secondary to multidrug-resistant herpes simplex virus 2 in an immunocompetent adolescent.
Topics: Adolescent; Antiviral Agents; Drug Resistance, Viral; Eye Infections, Viral; Foscarnet; Herpes Simpl | 2014 |
Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance.
Topics: Acyclovir; Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Child; Child, Preschool; DN | 2015 |
Brincidofovir clearance of acyclovir-resistant herpes simplex virus-1 and adenovirus infection after stem cell transplantation.
Topics: Acyclovir; Adenoviridae; Adenovirus Infections, Human; Antibiotic Prophylaxis; Antiviral Agents; Chi | 2016 |
Treatment of Refractory Acute Retinal Necrosis with Intravenous Foscarnet or Cidofovir.
Topics: Aged; Aged, 80 and over; Antiviral Agents; Cidofovir; Cytosine; Eye Infections, Viral; Foscarnet; He | 2018 |
Acyclovir resistance in herpes simplex virus type I encephalitis: a case report.
Topics: Acyclovir; Antiviral Agents; Disease Progression; Drug Resistance, Viral; Drug Substitution; Encepha | 2017 |
Acute retinal necrosis: the effects of intravitreal foscarnet and virus type on outcome.
Topics: Acyclovir; Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Child; Eye Infections, Vira | 2010 |
Long-term follow-up of acute retinal necrosis.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Child; Cytomegalovirus; Cytomegalovirus Infections; Drug | 2010 |
Extensive oral herpes simplex virus type 1 infection in a haematopoietic stem cell transplant recipient not responding to aciclovir.
Topics: Acyclovir; Antiviral Agents; Drug Resistance, Viral; Foscarnet; Hematopoietic Stem Cell Transplantat | 2011 |
Novel resistance-associated mutations of thymidine kinase and DNA polymerase genes of herpes simplex virus type 1 and type 2.
Topics: Acyclovir; Adolescent; Adult; Aged; Antiviral Agents; Bromodeoxyuridine; Child; Child, Preschool; Ci | 2011 |
Successful treatment of aciclovir and foscarnet resistant Herpes simplex virus lesions with topical imiquimod in patients infected with human immunodeficiency virus type 1.
Topics: Acyclovir; Administration, Topical; Adult; Aminoquinolines; Antiviral Agents; Drug Resistance, Viral | 2012 |
Successful clearance of cutaneous acyclovir-resistant, foscarnet-refractory herpes virus lesions with topical cidofovir in an allogeneic hematopoietic stem cell transplant patient.
Topics: Acyclovir; Administration, Topical; Adult; Antiviral Agents; Cidofovir; Cytosine; Drug Resistance, V | 2013 |
Bone marrow transplantation in a child with Wiskott-Aldrich syndrome latently infected with acyclovir-resistant (ACV(r)) herpes simplex virus type 1: emergence of foscarnet-resistant virus originating from the ACV(r) virus.
Topics: Acyclovir; Adolescent; Animals; Antiviral Agents; Base Sequence; Bone Marrow Transplantation; Cell L | 2002 |
Herpes simplex virus type 1 encephalitis associated with acute retinal necrosis syndrome in an immunocompetent patient.
Topics: Adult; Antiviral Agents; Aqueous Humor; Cerebrospinal Fluid; DNA, Viral; Encephalitis, Herpes Simple | 2002 |
[Antiretroviral drugs for the treatment and prevention of herpes infections in the year 2000].
Topics: Acyclovir; Antiviral Agents; Drug Resistance, Viral; Foscarnet; Herpes Simplex; Humans | 2002 |
[Acyclovir-resistant herpes exulcerans et persistens. Type II].
Topics: Acyclovir; Aged; Antiviral Agents; Drug Resistance, Microbial; Female; Foscarnet; Herpes Simplex; He | 2003 |
Herpes simplex virus pneumonia in a patient with ependymoma.
Topics: Acyclovir; Antiviral Agents; Brain Neoplasms; Child, Preschool; Drug Therapy, Combination; Ependymom | 2004 |
[Acute retinal necrosis: clinical presentation, treatment, and prognosis in a series of 22 patients].
Topics: Acyclovir; Adolescent; Adult; Aged; Antiviral Agents; Cytomegalovirus Retinitis; Drug Therapy, Combi | 2004 |
S-adenosyl methionine decarboxylase activity is required for the outcome of herpes simplex virus type 1 infection and represents a new potential therapeutic target.
Topics: Acyclovir; Adenosylmethionine Decarboxylase; Antiviral Agents; Cell Line; Cell Proliferation; Enzyme | 2005 |
Intravenous foscarnet in the management of acyclovir-resistant herpes simplex virus type 2 in acute retinal necrosis in children.
Topics: Acyclovir; Adolescent; Antiviral Agents; Child; Drug Resistance, Viral; Female; Foscarnet; Herpes Si | 2005 |
DNA polymerase mutations in drug-resistant herpes simplex virus mutants determine in vivo neurovirulence and drug-enzyme interactions.
Topics: Adenine; Animals; Antiviral Agents; Chlorocebus aethiops; Cidofovir; Cytosine; Disease Models, Anima | 2007 |
Successful liver transplantation in a kidney and pancreas allograft recipient with fulminant herpes simplex virus type 2 hepatitis.
Topics: Acyclovir; Adult; Antiviral Agents; Biopsy, Needle; Female; Foscarnet; Hepatitis, Viral, Human; Herp | 2007 |
Cutaneous herpes simplex virus infection of the guinea pig: lack of resistance to acyclovir and phosphonoformic acid after topical treatment.
Topics: Acyclovir; Administration, Topical; Animals; Drug Resistance, Microbial; Drug Therapy, Combination; | 1984 |
Combined chemotherapy of cutaneous herpes simplex infection of the guinea pig.
Topics: Acyclovir; Animals; Antiviral Agents; Arabinonucleosides; Deoxyuridine; Drug Therapy, Combination; F | 1983 |
Neuritic uptake and transport of antiviral drugs modifying herpes simplex virus infection of rat sensory neurons.
Topics: Acyclovir; Animals; Antigens, Viral; Biological Transport; Cells, Cultured; Female; Foscarnet; Gangl | 1984 |
Disseminating herpes simplex infection: primary lesions in urinary bladder and successful treatment with forscarnet sodium.
Topics: Adult; Female; Foscarnet; Herpes Simplex; Humans; Kidney Transplantation; Organophosphorus Compounds | 1984 |
Inhibition of herpesvirus multiplication in guinea pig skin by antiviral compounds.
Topics: Animals; Antiviral Agents; Cytarabine; Foscarnet; Guinea Pigs; Herpes Simplex; Idoxuridine; Male; Or | 1980 |
Persistent reactivable latent herpes simplex virus infection in trigeminal ganglia of mice treated with antiviral drugs.
Topics: Acyclovir; Animals; Antiviral Agents; Foscarnet; Guanine; Herpes Simplex; Idoxuridine; Male; Mice; M | 1981 |
Therapeutic effects of foscarnet sodium and acyclovir on cutaneous infections due to herpes simplex virus type 1 in guinea pigs.
Topics: Acyclovir; Administration, Topical; Animals; Dose-Response Relationship, Drug; Foscarnet; Guanine; G | 1982 |
Drugs for AIDS and associated infections.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Amphotericin B; Antifunga | 1995 |
Disseminated acyclovir-resistant herpes simplex virus type 2 treated successfully with foscarnet.
Topics: Acyclovir; Adult; Drug Resistance, Microbial; Foscarnet; Hand; Herpes Simplex; Herpesvirus 2, Human; | 1995 |
Successful treatment of progressive mucocutaneous infection due to acyclovir- and foscarnet-resistant herpes simplex virus with (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC).
Topics: Acyclovir; Administration, Topical; Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; | 1994 |
Correlation between response to acyclovir and foscarnet therapy and in vitro susceptibility result for isolates of herpes simplex virus from human immunodeficiency virus-infected patients.
Topics: Acyclovir; Female; Foscarnet; Herpes Simplex; HIV Infections; Humans; Male; Microbial Sensitivity Te | 1994 |
A rapid screen test for in vitro susceptibility of clinical herpes simplex virus isolates.
Topics: Acyclovir; Animals; Drug Resistance, Microbial; Evaluation Studies as Topic; Foscarnet; Herpes Genit | 1994 |
Acyclovir-resistant neonatal herpes simplex virus infection of the larynx.
Topics: Acyclovir; Drug Resistance, Microbial; Female; Foscarnet; Herpes Simplex; Herpesvirus 2, Human; Huma | 1994 |
[Acyclovir-resistant Herpes simplex viruses in HIV-infected patients].
Topics: Acyclovir; Adult; AIDS-Related Opportunistic Infections; Drug Resistance, Microbial; Female; Foscarn | 1993 |
Successful foscarnet therapy for acyclovir-resistant mucocutaneous infection with herpes simplex virus in a recipient of allogeneic BMT.
Topics: Acyclovir; Adult; Animals; Bone Marrow Transplantation; Chlorocebus aethiops; Esophagitis; Foscarnet | 1993 |
Foscarnet therapy for acyclovir-resistant herpes simplex virus 1 infection in allogeneic bone marrow transplant recipients.
Topics: Acyclovir; Adolescent; Adult; Antiviral Agents; Bone Marrow Transplantation; Drug Resistance, Microb | 1995 |
Comparative evaluation of microplate enzyme-linked immunosorbent assay versus plaque reduction assay for antiviral susceptibility testing of herpes simplex virus isolates.
Topics: Acyclovir; Antiviral Agents; Enzyme-Linked Immunosorbent Assay; Foscarnet; Herpes Simplex; Humans; M | 1996 |
Topical foscarnet for aciclovir-resistant mucocutaneous herpes infections in AIDS.
Topics: Acyclovir; Administration, Topical; Antiviral Agents; Chickenpox; Drug Resistance, Microbial; Foscar | 1997 |
Early foscarnet failure in herpes simplex virus infection in a patient with AIDS.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Foscarnet; Herpes Simplex; Humans; M | 1997 |
Flow cytometric analysis of herpes simplex virus type 1 susceptibility to acyclovir, ganciclovir, and foscarnet.
Topics: Acyclovir; Antiviral Agents; Fibroblasts; Flow Cytometry; Foscarnet; Ganciclovir; Herpes Simplex; He | 1997 |
Successful treatment of an acyclovir- and foscarnet-resistant herpes simplex virus type 1 lesion with intravenous cidofovir.
Topics: Acyclovir; Adult; Antiviral Agents; Cidofovir; Cytosine; Drug Resistance, Microbial; Drug Resistance | 1998 |
AIDS-related herpes simplex virus encephalitis during maintenance foscarnet therapy.
Topics: Adult; AIDS-Related Opportunistic Infections; Animals; Antiviral Agents; Cell Line; Chlorocebus aeth | 1998 |
Foscarnet decreases HIV-1 plasma load.
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Antiviral Agents; Cytomegalovirus Infections; Femal | 1998 |
Herpes simplex virus zosteriform lesions with adoptive transfer of immune cells: a murine model which mimics human recurrent disease.
Topics: Administration, Topical; Adoptive Transfer; Animals; Antiviral Agents; Cell Line; Cricetinae; Diseas | 1998 |
Treatment of acyclovir-resistant, foscarnet-unresponsive HSV infection with topical cidofovir in a child with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Anti-HIV Agents; Child, Preschool; Cidofovir; Cytosin | 1998 |
Treatment of acyclovir-resistant herpetic ulceration with topical foscarnet and antiviral sensitivity analysis.
Topics: Acyclovir; Administration, Topical; Antiviral Agents; Drug Resistance, Microbial; Female; Foscarnet; | 1998 |
Combinations of antiviral and anti-inflammatory preparations for the topical treatment of herpes simplex virus assessed using a murine zosteriform infection model.
Topics: Administration, Topical; Adoptive Transfer; Animals; Anti-Inflammatory Agents; Antiviral Agents; Dis | 1998 |
Images in clinical medicine. Severe herpes simplex infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Face; Foscarnet; Herpes Simplex; Hum | 1999 |
Characterization of the DNA polymerase and thymidine kinase genesof herpes simplex virus isolates from AIDS patients in whom acyclovirand foscarnet therapy sequentially failed.
Topics: Acyclovir; AIDS-Related Opportunistic Infections; Antiviral Agents; DNA-Directed DNA Polymerase; Dru | 1999 |
Treatment of herpes retinitis in an animal model with a sustained delivery antiviral drug, liposomal 1-O-octadecyl-SN-glycerol-3-phosphonoformate.
Topics: Animals; Antiviral Agents; Delayed-Action Preparations; Disease Models, Animal; Drug Carriers; Eye I | 1999 |
[Lumbosacral polyradiculomyelitis caused by herpes simplex virus (HSV) in a patient with AIDS].
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; DNA, Viral; Foscarnet; Herpes Simple | 1999 |
Reducing chorioretinal viral counts with intravitreal foscarnet injections in a rabbit model of Herpes simplex virus type-1 retinitis.
Topics: Administration, Topical; Animals; Choroid; Foscarnet; Herpes Simplex; Herpesvirus 1, Human; Ophthalm | 1999 |
Cytopathic effect inhibition assay for determining the in-vitro susceptibility of herpes simplex virus to antiviral agents.
Topics: Acyclovir; Antiviral Agents; Foscarnet; Herpes Simplex; Herpesvirus 1, Human; Herpesvirus 2, Human; | 1999 |
Efficacies of topical formulations of foscarnet and acyclovir and of 5-percent acyclovir ointment (Zovirax) in a murine model of cutaneous herpes simplex virus type 1 infection.
Topics: Acyclovir; Administration, Topical; Animals; Drug Administration Schedule; Female; Foscarnet; Herpes | 2000 |
Sodium lauryl sulfate increases the efficacy of a topical formulation of foscarnet against herpes simplex virus type 1 cutaneous lesions in mice.
Topics: Administration, Topical; Animals; Antiviral Agents; Cell Survival; Chemistry, Pharmaceutical; Chloro | 2000 |
Resistant herpes simplex virus type 1 infection: an emerging concern after allogeneic stem cell transplantation.
Topics: Acyclovir; Adolescent; Adult; Antiviral Agents; Child; Cidofovir; Cytosine; Drug Resistance, Microbi | 2000 |
Treatment of an acyclovir and foscarnet-resistant herpes simplex virus infection with cidofovir in a child after an unrelated bone marrow transplant.
Topics: Acyclovir; Antiviral Agents; Bone Marrow Transplantation; Cidofovir; Cytosine; Drug Resistance; Fema | 2000 |
Efficacies of gel formulations containing foscarnet, alone or combined with sodium lauryl sulfate, against establishment and reactivation of latent herpes simplex virus type 1.
Topics: Administration, Topical; Animals; Antiviral Agents; Drug Combinations; Foscarnet; Gels; Herpes Simpl | 2001 |
New indication for foscarnet.
Topics: Antiviral Agents; Drug Approval; Foscarnet; Herpes Simplex; Humans; Immunocompromised Host; United S | 1995 |
New drug applications sought.
Topics: AIDS-Related Opportunistic Infections; Clarithromycin; Cytomegalovirus Retinitis; Drug Approval; Dru | 1995 |
Foscavir receives new indication.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Retinitis; Drug Therapy, Co | 1997 |
Herpes study and resources.
Topics: 2-Aminopurine; Acyclovir; Adult; Antiviral Agents; Biopolymers; Catechin; Clinical Trials as Topic; | 1997 |
Infection due to acyclovir resistant herpes simplex virus in patients undergoing allogeneic hematopoietic stem cell transplantation.
Topics: Acute Disease; Acyclovir; Adolescent; Amino Acid Substitution; Antiviral Agents; Bone Marrow Transpl | 2001 |
Successful treatment of foscarnet-resistant herpes simplex stomatitis with intravenous cidofovir in a child.
Topics: Acyclovir; Antiviral Agents; Bone Marrow Transplantation; Child; Cidofovir; Cytosine; Drug Resistanc | 2001 |
Development of acyclovir-resistant herpes simplex virus early during the treatment of herpes neonatorum.
Topics: Acyclovir; Antiviral Agents; Autopsy; DNA, Viral; Drug Resistance, Viral; Fatal Outcome; Female; Fos | 2001 |
Multiple herpes simplex virus infections with various resistance patterns in a matched unrelated donor transplant recipient.
Topics: Acyclovir; Antineoplastic Agents, Alkylating; Antiviral Agents; Bone Marrow Transplantation; Cidofov | 2001 |
Development of drug-resistant herpes simplex virus infection after haploidentical hematopoietic progenitor cell transplantation.
Topics: Acyclovir; Adult; Antiviral Agents; Drug Resistance, Viral; Female; Foscarnet; Haplotypes; Hematolog | 2002 |
[In vitro susceptibility study of herpes simplex virus to acyclovir and foscarnet. Are routine susceptibility studies necessary?].
Topics: Acyclovir; Antiviral Agents; Diagnostic Tests, Routine; Drug Resistance, Viral; Foscarnet; Herpes Si | 2002 |
Herpes simplex virus isolates with reduced adefovir susceptibility selected in vivo by foscarnet therapy.
Topics: Adenine; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Foscarnet; Herpes Genitalis; Herpes | 2002 |
Clinical implications of herpesvirus infections in patients with AIDS. Introduction.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Eye Infections, Vi | 1992 |
[Acyclovir-resistant herpes simplex virus infections in immunocompromised patients].
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Adult; Antiviral Agents; Bone Transplantation; Drug R | 1992 |
Clinical effects and in vitro studies of trifluorothymidine combined with interferon-alpha for treatment of drug-resistant and -sensitive herpes simplex virus infections.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Adult; Antiviral Agents; Combined Modality Therapy; C | 1992 |
Herpes simplex virus infection during foscarnet therapy.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; | 1992 |
Experimental in vivo generation of intertypic recombinant strains of HSV in the mouse.
Topics: Animals; Female; Foscarnet; Ganglia, Sympathetic; Herpes Simplex; Mice; Mice, Inbred Strains; Phosph | 1992 |
Heterogeneity of a herpes simplex virus clinical isolate exhibiting resistance to acyclovir and foscarnet.
Topics: Acyclovir; Animals; Drug Resistance, Microbial; Foscarnet; Genetic Variation; Herpes Simplex; Humans | 1992 |
[Type 1 herpesvirus cutaneo-mucous infection resistant to aciclovir in a HIV infected patient. Clinical and virological study].
Topics: Acyclovir; Adult; Antiviral Agents; Drug Resistance, Microbial; Foscarnet; Herpes Simplex; HIV Infec | 1992 |
Foscarnet-induced hypocalcemia and effects of foscarnet on calcium metabolism.
Topics: Antiviral Agents; Calcium; Dose-Response Relationship, Drug; Foscarnet; Herpes Simplex; Humans; Hypo | 1991 |
Herpes simplex virus type-2 ulcers resistant to acyclovir in an AIDS patient--successful treatment with foscarnet.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Adult; Antiviral Agents; Anus Diseases; Drug Resistan | 1991 |
Acyclovir resistance/susceptibility in herpes simplex virus type 2 sequential isolates from an AIDS patient.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Adult; Drug Resistance, Microbial; Follow-Up Studies; | 1991 |
Foscarnet effective in acyclovir-resistant herpes.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Antiviral Agents; Drug Resistance, Microbial; Foscarn | 1991 |
Foscarnet and penile ulceration.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; Herpes | 1990 |
[Aciclovir-resistant herpes simplex virus infection in an immuno-depressed patient. Favourable effect of foscarnet].
Topics: Acyclovir; Antiviral Agents; Drug Resistance, Microbial; Foscarnet; Herpes Simplex; HIV Seropositivi | 1990 |
Heterotypic and homotypic re-inoculation of mice already latently infected with herpes simplex virus type 1.
Topics: Animals; Antiviral Agents; Drug Resistance, Microbial; Female; Foscarnet; Herpes Simplex; Mice; Mice | 1990 |
Foscarnet therapy for acyclovir-resistant mucocutaneous herpes simplex virus infection in 26 AIDS patients: preliminary data.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Adult; Drug Resistance, Microbial; Female; Foscarnet; | 1990 |
Acyclovir-resistant herpes simplex virus causing pneumonia after marrow transplantation.
Topics: Acyclovir; Adult; Animals; Antiviral Agents; Bone Marrow Transplantation; Cells, Cultured; Drug Resi | 1990 |
Altered sensitivity to antiviral drugs of herpes simplex virus isolates from a patient with the acquired immunodeficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Adult; Antiviral Agents; Aphidicolin; Deoxyguanosine; | 1990 |
Foscarnet therapy for severe acyclovir-resistant herpes simplex virus type-2 infections in patients with the acquired immunodeficiency syndrome (AIDS). An uncontrolled trial.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Adult; Antiviral Agents; Drug Resistance, Microbial; | 1989 |
Acyclovir-resistant, foscarnet-sensitive oral herpes simplex type 2 lesion in a patient with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Adult; Antiviral Agents; Candidiasis, Oral; Drug Resi | 1989 |
Successful treatment with foscarnet of an acyclovir-resistant mucocutaneous infection with herpes simplex virus in a patient with acquired immunodeficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Adult; Antiviral Agents; Drug Resistance, Microbial; | 1989 |
Therapeutic effect of (E)-5-(2-bromovinyl)-2'-deoxyuridine, caffeic acid oxidation product, and trisodiumphosphonoformate on cutaneous herpes simplex virus type 1 infection in guinea pigs.
Topics: Animals; Antiviral Agents; Bromodeoxyuridine; Caffeic Acids; Cinnamates; Female; Foscarnet; Guinea P | 1987 |
Limited efficacy of inhibitors of herpes simplex virus DNA synthesis in murine models of recrudescent disease.
Topics: Acyclovir; Administration, Oral; Administration, Topical; Animals; Antiviral Agents; Disease Models, | 1988 |
Efficacy of 5-vinyl-1-beta-D-arabinofuranosyluracil (VaraU) against herpes simplex virus type 2 strains in cell cultures and against experimental herpes encephalitis in mice: comparison with acyclovir and foscarnet.
Topics: Acyclovir; Animals; Antiviral Agents; Arabinofuranosyluracil; Cells, Cultured; Encephalitis; Female; | 1987 |
Herpes simplex virus hepatitis in mice: effects of treatment with trisodium phosphonoformate.
Topics: Animals; Antiviral Agents; Disease Models, Animal; Foscarnet; Hepatitis, Viral, Animal; Herpes Simpl | 1985 |
Comparison of foscarnet cream, acyclovir cream, and acyclovir ointment in the topical treatment of experimental cutaneous herpes simplex virus type 1 infection.
Topics: Acyclovir; Administration, Topical; Animals; Female; Foscarnet; Guinea Pigs; Herpes Simplex; Ointmen | 1986 |
The effects of topical foscarnet in a new model of herpes simplex skin infection.
Topics: Administration, Cutaneous; Animals; Antiviral Agents; Disease Models, Animal; Foscarnet; Herpes Simp | 1987 |
Combination chemotherapy: interaction of 5-methoxymethyldeoxyuridine with trifluorothymidine, phosphonoformate and acycloguanosine against herpes simplex viruses.
Topics: Acyclovir; Animals; Antiviral Agents; Deoxyuridine; DNA, Viral; Drug Combinations; Drug Resistance, | 1985 |
Clinical experiences with phosphonoformate (foscarnet) treatment of viral diseases following renal transplantation.
Topics: Adult; Aged; Antiviral Agents; Cytomegalovirus Infections; Female; Foscarnet; Herpes Simplex; Herpes | 1985 |
Treatment of experimental herpes simplex virus type 1 encephalitis in mice with (E)-5-(2-bromovinyl)- and 5-vinyl-1-beta-D-arabinofuranosyluracil: comparison with bromovinyl-deoxyuridine and acyclovir.
Topics: Acyclovir; Animals; Arabinofuranosyluracil; Bromodeoxyuridine; Cells, Cultured; Encephalitis; Female | 1986 |
Anti-herpes virus combinations in relation to drug resistance.
Topics: Acyclovir; Adenosine Deaminase Inhibitors; Animals; Antiviral Agents; Diphosphates; Drug Resistance, | 1986 |
Nucleoside pools of acyclovir-treated herpes simplex type 1 infected cells.
Topics: Acyclovir; Animals; Cells, Cultured; Chlorocebus aethiops; Foscarnet; Herpes Simplex; Humans; Kineti | 1985 |